In the News

October 23, 2008--Nature.com Solid-state quantum memory using the 31 P nuclear spin
Nature.com (subscription),  UK  -
Pulsed EPR experiments were performed using an X-band (9–10 GHz) Bruker EPR spectrometer (Elexsys 580) equipped with a low-temperature helium-flow cryostat .

Abstract

The transfer of information between different physical forms—for example processing entities and memory—is a central theme in communication and computation. This is crucial in quantum computation 1 , where great effort 2 must be taken to protect the integrity of a fragile quantum bit (qubit). However, transfer of quantum information is particularly challenging, as the process must remain coherent at all times to preserve the quantum nature of the information. Here we demonstrate the coherent transfer of a superposition state in an electron-spin 'processing' qubit to a nuclear-spin 'memory' qubit, using a combination of microwave and radio-frequency pulses applied to 31 P donors in an isotopically pure 28 Si crystal The state is left in the nuclear spin on a timescale that is long compared with the electron decoherence time, and is then coherently transferred back to the electron spin, thus demonstrating the 31 P nuclear spin as a solid-state quantum memory. The overall store–readout fidelity is about 90 per cent, with the loss attributed to imperfect rotations, and can be improved through the use of composite pulses. The coherence lifetime of the quantum memory element at 5.5 K exceeds 1 s. Correspondence to: John J. L. Morton (Email:  john.morton@materials.ox.ac.uk ).

http://www.nature.com/nature/journal/v455/n7216/full/nature07295.html      ..

J. Willmann, D. Leibfritz, H. Thiele : Hyphenation Tools for Phospholipidomics in J. Biomolecular Tech. Vol. 19(3), July 2008.

BioTech News—October 14, 2008--:

La Trobe specs its mass

Four new mass spectrometers take up residence at La Trobe

Kate McDonald (Australian Life Scientist)

La Trobe University has launched its new mass spectrometry facility at its molecular sciences laboratories in Bundoora.   Funds from the CRC for Biomarker Translation and an ARC LIEF grant have enabled the university's biochemistry department to purchase four new mass specs from Bruker Daltonics and to move an Applied Biosystems' QStar LC/MS/MS from CSIRO Parkville to La Trobe.

The new Bruker machines are an ultraflex MALDI-TOF, a micrOTOF-Q, an HCTultra ESIO-Ion Trap MS with electron transfer dissociation and an Esquire ESI-Ion Trap.   The funds have also allowed the facility to purchase some spotting robots, a database and server and four Dionex Ultimate 3000 capillary LC systems.

La Trobe's deputy vice chancellor for research, Professor Tim Brown, said the university had researched every major supplier of proteomic instrumentation for its requirements.   “Usually you get high accuracy or high throughput,” Brown said in a statement. “The gold standard is to try to have equipment that does both. These machines approach that.”

The facility's manager, Vince Murphy, said the instrumentation would be used both by the biochemistry and chemistry departments and for collaborative and commercial research, including the CRC.

November 2008—European Biopharmaceutical Review published an article by Bruker’s Director of Bioinformatics, Professor Dr. Herbert Thiele, describing all the new developments with Bruker’s new ProteinScape 2 bioinformatics platform for proteomics. Please click here to read the PDF.

Bruker Director Describes Design Methodology of Advanced Proteinscape 2 Bioinformatics Platform

The American Diabetes Association's Diabetes journal just published: Increase in
Endoplasmic Reticulum Stress–Related Proteins and Genes in Adipose Tissue of
Obese, Insulin-Resistant Individuals

Guenther Boden 1 , Xunbao Duan 2 , Carol Homko 1 , Ezequiel J. Molina 3 ,
WeiWei Song 1 , Oscar Perez 2 , Peter Cheung 1 , and Salim Merali 2

1 Division of Endocrinology, Diabetes, and Metabolism and the Clinical Research Center,
Temple University School of Medicine, Philadelphia, Pennsylvania
2 Department of Biochemistry, Temple University School of Medicine, Philadelphia , Pennsylvania
3 Department of Surgery, Temple University School of Medicine, Philadelphia , Pennsylvania

Corresponding author: Guenther Boden, bodengh@tuhs.temple.edu

OBJECTIVE— To examine fat biopsy samples from lean insulin-sensitive and obese insulin-resistant nondiabetic individuals for evidence of endoplasmic reticulum (ER) stress.

RESEARCH DESIGN AND METHODS— Subcutaneous fat biopsies were obtained from the upper thighs of six lean and six obese nondiabetic subjects. Fat homogenates were used for proteomic (two-dimensional gel and MALDI-TOF/TOF), Western blot, and RT-PCR analysis.

RESULTS— Proteomic analysis revealed 19 differentially upregulated proteins in fat of obese subjects. Three of these proteins were the ER stress–related unfolded protein response (UPR) proteins calreticulin, protein disulfide-isomerase A3, and glutathione- S -transferase P. Western blotting revealed upregulation of several other UPR stress–related proteins, including calnexin, a membrane-bound chaperone, and phospho c-jun NH 2 -terminal kinase (JNK)-1, a downstream effector protein of ER stress. RT-PCR analysis revealed upregulation of the spliced form of X-box binding protein-1s, a potent transcription factor and part of the proximal ER stress sensor inositol-requiring enzyme-1 pathway.

CONCLUSIONS— These findings represent the first demonstration of UPR activation in subcutaneous adipose tissue of obese human subjects. As JNK can inhibit insulin action and activate proinflammatory pathways, ER stress activation of JNK may be a link between obesity, insulin resistance, and inflammation.
http://diabetes.diabetesjournals.org/cgi/content/abstract/db08-0604v1

(NewsRx.com) -- New investigation results, 'Detection of microcystin-metal complexes by using cryospray ionization-Fourier transform ion cyclotron resonance mass spectrometry ,' are detailed in a study published in Toxicon . According to recent research published in the journal Toxicon , "Complexes of microcystins (MCs) and metal ions were detected with mass spectrometry. To observe the MCs-metals complexes, CryoSpray ionization ion source was developed and it was equipped on a commercial Fourier transform ion resonance mass spectrometer."

"Mixtures of two MCs and five metals were applied to Fourier transform ion cyclotron resonance mass spectrometry coupled with CryoSpray. The analyses showed complexes of MC-LR-Fe(II), -Zn, -Cu, -Mg, MC-RR-Fe(II), -Zn, -Cu, and -Mg but MC-LR-Fe(III) and MC-RR-Fe(III) were not observed," wrote K. Saito and colleagues, Bruker.

The researchers concluded: "Present study suggested that MCs may play roles in metal ion uptake and/or accumulation in the algal cells."

Saito and colleagues published their study in Toxicon (Detection of microcystin-metal complexes by using cryospray ionization-Fourier transform ion cyclotron resonance mass spectrometry. Toxicon , 2008;51(8):1496-8).

For additional information, contact K. Saito, Bruker Daltonics KK, 3-9 A-6F Moriya-cho, Kanagawa-ku, Yokohama , Kanagawa , Japan .

The publisher's contact information for the journal Toxicon is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane , Kidlington, Oxford OX5 1GB, England .

August 26, 2008-- Scientists at the Nuclear-Magnetic Resonance unit at the University of Warwick have discovered how a high tech glass of milk is helping bones mend.

Low temperature Bioglass is used to help fix broken bones, but until now no-one has been able to understand the process.

Using a strong magnetic field to ‘see' into the bones researchers saw calcium rush into the bioglass in the first hour of implantation.

Physicist Professor Mark Smith explains: “Bioglass is used to help mend broken bones. Recently researchers working at Imperial College discovered a new kind of bioglass which seemed to work better, but they could not work out all the details why.

“We looked at it through our NMR machine and were amazed by what we saw. Fluid simulating patient's bodies rushed calcium out of the bioglass and then into the new bones. It seems perhaps a glass-of-milk-a-day really is what the doctor ordered.”

The new Bioglass uses chemicals rather than heat to form the replacement bones. The University of Warwick worked with Imperial College and Kent University of the project.

August 2008--Agence France-Presse published:
Cracking Ice Age dress code a shot-in-the-arm for fashionistas--
PARIS (AFP) — Methods used to crack the dress code of Oetzi the Iceman, whose mummified remains turned up in an Alpine glacier almost two decades ago, could be a boon to the clothing industry, a new study showed Wednesday.
Analysing samples of his more then 5,000-year-old Neolithic clothing, "we found the hairs came from sheep and cattle, the type of animals herdsmen care for during their seasonal migrations," said Klaus Hollemeyer of Germany's Saarland University and lead researcher of the study.
Specifically, his coat and leggings were made from sheep's fur and his mocassins were of cattle origin, according to the study, published in the journal Rapid Communications in Mass Spectrometry .
Hollemeyer told AFP that the method used to study the samples -- known as MALDI-TOF mass spectrometry -- was faster and more reliable than methods based on DNA analysis.
"This method could for example be used in checking the purity of products made from animal hair, such as Cashmere wool ," he said.
It could also prove particularly useful to clothes manufacturers next year when the European Union enforces a ban on dog and cat fur trade.
Hollemeyer said that DNA sampling was less reliable, specially in processed furs or animal wool, as DNA can be destroyed during tanning, bleaching and colouring.
"The same often happens with archaeological samples stored under non-optimal conditions," he added.
MALDI stands for Matrix-assisted laser desorption/ionization. TOF is the "time-of-flight" type of mass spectrometer most widely used with MALDI.
"The method is fast, can be done within a few hours and is reliable," Hollemeyer said.

http://news.nationalgeographic.com/news/2008/08/080821-iceman-clothes_2.html

http://mass-spec.lsu.edu/blog/

September 2008—BONE, the official journal of the International Bone and Mineral Society, published this paper by Taiwan scientists using their Bruker MALDI-TOF/TOF mass spectrometer at the Chang Gung Memorial Hospital-Kaohsiung Medical Center and the Chang Gung University College of Medicine:

Comparative serum proteome expression of osteonecrosis of the femoral head in adults

Osteonecrosis of the femoral head (ONFH) is a skeletal disorder characterized by ischemic deterioration, bone marrow edema and eventually femoral head collapse. The systemic regulation of ONFH in adult patients has not been examined. Serum proteomic is an innovative tool that potentially detects simultaneous expressions of serum proteins in pathological contexts. We compared the serum proteome profiles of 11 adult patients with ONFH (3 females and 8 males) and 11 healthy volunteers (3 females and 8 males). The proteins in the aliquots of sera were subjected to isoelectric focusing, two-dimensional gel electrophoresis and silver staining. The protein spots were matched and quantified using an imaging analysis system. The differentially expressed protein spots were subjected to in-gel trypsin digestion. The peptide mass fingerprints were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/TOF) and a bioinformation search. We found that ONFH patients showed significantly higher abundances of kininogen 1 variant, complement factor C3 precursor, and complement factor H and lower levels of antithrombin III chain B, apolipoprotein A--IV precursor, and gelsolin isoform α precursor. These proteins of interest were reported to modulate thrombotic/fibrinolytic reactions, oxidative stress, vessel injury, tissue necrosis or cell apoptosis in several tissue types under pathological contexts. Taken together, the occurrence of ONFH was associated with various serum protein expressions. Our high--throughput serum proteomic findings indicated that multiple pathological reactions presumably occurred in ONFH.

Re-Wen Wua1, Feng-Sheng Wangbc1, Jih-Yang Koac, Ching-Jen Wangac, Shin-Long Wub

a.) Department of Orthopedic Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan b.) Department of Medical Research, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Taiwan c.) Graduate Institute of Clinical Medical Science, Chang Gung University College of Medicine, Kaohsiung, Taiwan
http://www.journals.elsevierhealth.com/periodicals/bon/article/PIIS8756328208002305/abstract?rss=yes

Aug 7, 2008 –KSFY TV-- Is that tumor cancerous, and how fast might it spread?

Pathologists have to answer those tricky questions every day.  Now a tool.normally found in crime labs.is in the hands of doctors to help them do a better job of catching cancer.  This is what a doctor sees viewing a tumor biopsy under a microscope. They have to judge by cells' visible features whether they're cancerous and if so, how aggressive.  "If you wanted to look at the edge of a tumor, one of the things that you want to know is that edge rapidly growing, is it an aggressive edge, or is it somewhat dormant or is the tumor not going to grow?" Now biochemist Richard Caprioli is helping them to also see the molecules involved in cancer and its spread. "Each one of those colors represents a different molecular signature that describes those different aggressive, less aggressive, and normal tissue levels." He and his team at Vanderbilt University are developing what they call molecular imaging. It uses an instrument called a Mass Spectrometer, long used by chemists in places like crime labs. It detects the types and amounts of the various molecules in a sample….

Multimedia

• Watch The Video

July 2008—GIT Laboratory Journal Europe published a cover story about the new Bruker maXis mass spectrometer;

At ASMS 2008, Bruker Daltonics announced the maXis, a revolutionary new Electrospray Ultra-High Resolution tandem TOF mass spectrometer. The instrument was designed to meet head-on the biggest challenge in discovery LCMS today: to deliver ultra-high performance mass spectrometry data at speeds capable to fully exploit modern Ultra Performance Liquid Chromatography. The resulting instrument provides the definitive solution to future requirements in applications including small molecule identification, metabolomics, quantitative proteomics, and biomarker discovery. maXis redefines the scientist’s expectations of what can be achieved under LCMS conditions.

North Carolina Independent Tribune, July 31-- The magnets are coming-

The powerful nuclear magentic resonance spectrometers - the machines that will allow scientists to look at proteins and complex molecules at the sub-atomic level - will be installed at the (North Carolina Campus)Core Research Laboratory next week, said Steve Leath, president of the David H. Murdock Research Institute.

The NMR array, which includes the world's only 950 mHz spectrometer, will give researchers at the campus the best and most detailed images of molecules ever created. Castle & Cooke spokeswoman Phyllis Beaver said workers at the Core Lab will begin installing the magnets Monday morning, but there won't be a big announcement or media event. "It will probably begin Monday," Beaver said. "We're trying to move forward."
Bruker won the contract to furnish the Core Lab with the spectrometers.

June 2008 -- Scientists study water in nanotubes

LIVERMORE, Calif., June 30 (UPI) -- U.S. government scientists say they have moved closer to understanding how water is structured and how it moves inside single-walled carbon nanotubes.

Researchers at the U.S. Energy Department's Lawrence Livermore National Laboratory said they have identified a signature for water inside single-walled carbon nanotubes, or SWCNTs -- the first time researchers have been able to obtain such a "snapshot" inside the nanotubes, which offer the potential to act as a unique nanofiltration system.

LLNL scientists Jason Holt and Julie Herberg (a user of Bruker BioSpin Avance spectrometer systems at 400 and 500 MHz) , with the University of North Carolina's Yue Wu and colleagues, said they used a technique called nuclear magnetic resonance, or NMR, to get a glimpse of the water confined inside one-nanometer diameter SWCNTs.

The nanotubes are hollow and more than 50,000 times thinner than a human hair. The confined water exhibited very different properties from that of bulk water, allowing it to be distinguished in the NMR spectrum.

"There have been many predictions about how water behaves within carbon nanotubes," said Holt, the project's principal investigator. "With experiments like these, we can directly probe that water and determine how close those predictions were."

The research appears in the journal Nanoletters.

April 2008-- Editors Favor Innovation at Pittcon® ’08

December/January 2008 2008—BioIT World published an article by Bruker’s Professor Dr. Thiele, Director of Bioinformatics, entitled…

September 2007 The International Union of Crystallography's Journal of Crystallography recently published a research paper by a distinguished group of scientists, including Bruker AXS' Dan Frankel:

Operator-assisted harvesting of protein crystals using a universal micromanipulation robot

Abstract: High-throughput crystallography has reached a level of automation where complete computer-assisted robotic crystallization pipelines are capable of cocktail preparation, crystallization plate setup, and inspection and interpretation of results. While mounting of crystal pins, data collection and structure solution are highly automated, crystal harvesting and cryocooling remain formidable challenges towards full automation. To address the final frontier in achieving fully automated high-throughput crystallography, the prototype of an anthropomorphic six-axis universal micromanipulation robot (UMR) has been designed and tested; this UMR is capable of operator- assisted harvesting and cryoquenching of protein crystals as small as 10 µm from a variety of 96-well plates. The UMR is equipped with a versatile tool exchanger providing full operational flexibility. Trypsin crystals harvested and cryoquenched using the UMR have yielded a 1.5 Å structure demonstrating the feasibility of robotic protein crystal harvesting.

September 2007--Practicing Oil Analysis published an article by Bruker AXS scientists entitled "Elemental Analysis of Petrochemical Products".

Multielement analysis in the petrochemical industry is increasingly handled by X-ray spectroscopy (XRS). The popularity of this technique and instrumentation lies in the inherent advantages of using X-rays instead of light as the excitation source.....

September 7, 2007- The University of Wisconsin Business NewsWire writes:

A Recipe for Success

Software collaboration is winner for Bruker, UW-Madison

By Melissa Davis

It can safely be said that Madison-based biotech firm Bruker AXS as one of only two companies in the world that manufactures analytical X-ray systems is at the forefront of its field.http://buswire.ocr.wisc.edu/leadstory/200709.php

September 4, 2007Sergei Dikler of Bruker Daltonics co-published a paper in the Journal of Comparative Neurology. This is the third paper that resulted from the Bruker collaboration with University of Wisconsin Madison. It is focused on using sequences of 3 novel neuropeptides to clone a novel neuropeptide gene. Three sequences were established by de novo sequencing using MALDI-TOF/TOF spectra acquired on an Ultraflex directly from tissue. The full reference is provided below.

Yew JY, Davis R, Dikler S, Nanda J, Reinders B, Stretton AO. Peptide products of the afp-6 gene of the nematode Ascaris suum have different biological actions. J.
Comparative Neurology 2007; 502: 872.

The link to the abstract on the PubMed site is provided here

August, 23,2007 Bruker Daltonics Announces Selection of its Range of Chemical Agent Detectors for Slovenian Armored Vehicles

August 2007--Korean SBS television showed a Bruker Daltonics Autoflex MALDI-TOF mass spectrometer in operation in the Republic of South Korea.

August 2007-- The Journal of the American Society for Mass Spectrometry published papers involving Bruker Daltonics scientists and Bruker Daltonics FTMS and HCTultra PTM Discovery ion trap mass spectrometry: "The Combination of Electron Capture Dissociation and Fixed Charge Derivatization Increases Sequence Coverage for O-Glycosylated and O-Phosphorylated Peptides", along with "Improved Sequencing of Oxidized Cysteine and Methionine Containing Peptides Using Electron Transfer Dissociation".

June/July 2007--American Laboratory wrote: Bruker AXS, in cooperation with The Microbeam Analysis Society (MAS), has announced the creation of a new award, the Duncumb Award for Excellence in Microanalysis. The award honors the seminal contributions to the field of microanalysis made by Peter Duncumb, who developed X-ray mapping more than 50 years ago and was also instrumental in the development of analytical electron microscopy. This year's recipient is Prof. David Williams of Lehigh University. For more information, visit www.bruker-axs-ma.com or call 609-771-4400.

June 2007--Bruker Daltonics Asia/Pacific Vice President Clive Seymour was interviewed by Biotech World in their in-depth cover story (in simplified Chinese).

June 2007--CBRNe World's lead story for June starts off:

Gwyn Winfield examines the latest news in the world of CBRN

Product Watch

Gothenburg wrap up
As was expected Gothenburg (Sweden) saw a great deal of new toys unwrapped at the symposium. Bruker Daltonics celebrated the birth of the E2M (Environmental, Emergency Mass Spectrometer) with a champagne reception. This is the successor to their EM640 and Viking GC/MS and while not man-portable, ....., it is a significant improvement in terms of performance and physical envelope. http://www.cbrneworld.com/news_06_07.html

1
A complete set of line parameters for CH3Br in the 10-µm spectral region Journal of Quantitative Spectroscopy and Radiative Transfer, Volume 105, Issue 2, June 2007, Pages 264-302 D. Jacquemart, F. Kwabia Tchana, N. Lacome and I. Kleiner

2.
Serum Biomarkers to Differentiate Benign and Malignant Mammographic Lesions Journal of the American College of Surgeons, Volume 204, Issue 5, May 2007, Pages 1065-1071 Susanna Shin, Lisa Cazares, Heather Schneider, Shamina Mitchell, Christine Laronga, O. John Semmes, Roger R. Perry and Richard R. Drake

3.
Structural investigation of the CeRh2Sb2-x compound Journal of Alloys and Compounds, Volume 431, Issues 1-2, 4 April 2007, Pages 85-
88
C. Rizzoli, O.L. Sologub, L.P. Salamakha and A.P. Gonçalves

4.
Line intensity measurements in 14N216O and their treatment using the effective dipole moment approach.II. The 5400-11 000 cm-1 region Journal of Quantitative Spectroscopy and Radiative Transfer, Volume 104, Issue 3, April 2007, Pages 342-356 Ludovic Daumont, Jean Vander Auwera, Jean-Luc Teffo, Valery I. Perevalov and Sergeï A. Tashkun

5.
UF6 enrichment measurements using TDLS techniques Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Volume 66, Issues 4-5, April 2007, Pages 796-802 A.G. Berezin, S.L. Malyugin, A.I. Nadezhdinskii, D.Yu. Namestnikov, Ya.Ya.
Ponurovskii, D.B. Stavrovskii, Yu.P. Shapovalov, I.E. Vyazov, V.Ya. Zaslavskii, Yu.G.
Selivanov, et al.

6.
Atomoxetine produces changes in cortico-basal thalamic loop circuits: Assessed by phMRI BOLD contrast Neuropharmacology, Volume 52, Issue 3, March 2007, Pages 812-826 Neil Easton, Fiona Marshall, Kevin Fone and Charles Marsden

7.
Comparison of functional activity in the rat cervical spinal cord during alpha- chloralose and halothane anesthesia NeuroImage, Volume 34, Issue 4, 15 February 2007, Pages 1665-1672 Jane Lawrence, Patrick W. Stroman and Krisztina L. Malisza

8.
Direct profiling of myelinated and demyelinated regions in mouse brain by imaging mass spectrometry International Journal of Mass Spectrometry, Volume 260, Issues 2-3, 1 February 2007, Pages 185-194 Ruben Ceuppens, Debora Dumont, Leen Van Brussel, Babs Van de Plas, Ruth Daniels, Jean-Paul Noben, Peter Verhaert, Estel Van der Gucht, Johan Robben, Stefan Clerens, et al.

9.
Multispectrum fitting of line parameters for 12C2H2 in the 3.8-µm spectral region Journal of Quantitative Spectroscopy and Radiative Transfer, Volume 103, Issue 3, February 2007, Pages 478-495 D. Jacquemart, N. Lacome, J.-Y. Mandin, V. Dana, O.M. Lyulin and V.I. Perevalov

June 15, 2007--The Boston Business Journal named Bruker BioSciences President and CEO Frank H. Laukien as its CEO of the Week.

May 22, 2007-The Boston Globe today announced its Boston Globe 100 awards for its determination of the top 100 companies in Massachusetts. Bruker BioSciences is ranked number 41 overall in Massachusetts.

May 9, 2007-- Bloomberg News reported that Bruker BioSciences Corp. (BRKR) has just been rated "outperform" in new coverage by analyst John L Sullivan at Leerink Swann & Co.

May 2007-Nature Methods published a new Bruker Daltonics application note entitled "MALDI tissue imaging: mass spectrometric localization of biomarkers in tissue slices". New mass-spectrometric proteomics technologies have been developed with the potential to transition from pure research applications into the diagnostic laboratory. Of these, one very promising technique has already gained much interest in the research community: matrix-assisted laser desorption/ionization (MALDI) molecular imaging. For easy and successful application of MALDI imaging in the laboratory, Bruker Daltonics offers an innovative product line: a stand-alone automated sample preparation device, ImagePrep(TM), Bruker mass spectrometers with vital smartbeam(TM) technology: namely the Bruker autoflex III(TM) and Bruker ultraflex III(TM) MALDI-tandem time-of-flight (MALDI-TOF/TOF) instruments, and sophisticated software tools for fast data evaluation and biomarker visualization, fleximaging(TM). Key topics discussed include Tissue Preparation for MALDI Imaging, Gentle Matrix Application by ImagePrep, Real-Time Preparation Quality Control, Acquisition of High-Quality Spectra, and ImagePrep Completes the MALDI Molecular Imager Suite.

March 12, 2007--Bio-IT World interviewed Bruker Daltonics' Dr. Herbert Thiele, Worldwide Director of Bioinformatics, for its Champions 2.0 article.

March 1, 2007-- PITTCON Today, in its front page story "Editors Find Gold", reported that Bruker AXS tied for the Pittcon 2007 Editors' Choice Bronze Medal for the introduction of its new FT-IR Alpha, the world's smallest entry level FT-IR spectrometer. It is an entry level, easy to use FT-IR spectrometer, ideal for academic teaching and quality control labs. The ALPHA can be used for raw material identification of unknown materials as well as quality assurance for various industries, including pharmaceuticals, plastics and chemicals.

Bruker Daltonics's RAID-AFM, an automated facility monitor, won an honorable mention. The new RAID(TM)-AFM (Autonomous Facility Monitor) is designed to monitor large buildings and facilities for accidents or attacks involving toxic industrial chemicals or chemical warfare agents. Bruker AXS' MICROSTAR ULTRA(TM) also won an honorable mention. The new MICROSTAR ULTRA, an ultra-bright laboratory X-ray source for structural biology, is comparable in brightness to many second-generation synchrotron beamlines. Utilizing novel electron optics and the revolutionary new Hypercool(TM) cooling design (patent applied for), the MICROSTAR ULTRA produces unrivalled X-ray intensities, which are beneficial for all aspects of in-house crystallographic research, from high-throughput crystal screening to structure determinations with SAD phasing.

PITTCON Today said, "As always, new products and technology were everywhere during Pittcon 2007. More than 150 editors and reporters from around the world searched out products they believe should be brought to the attention of our readers...The Exposition is enormous, with more than a thousand exhibitors.... Products or technologies selected must be on the Exposition floor."

January 24, 2007--DrugResearcher.com interviewed Dr Detlev Suckau, head of MALDI-applications development and proteomics at Bruker Daltonics, for an article entitled "Bruker brings imaging to the masses."

Bruker Daltonics has launched a new technology that could accelerate the use of MALDI imaging in drug discovery labs by simplifying sample preparation procedures.

December 2006--SCREENING magazine published a Bruker Daltonics application note entitled "MALDI Fingerprinting of Bacteria-Arrest the Culprit, Fast". Traditional methods of identification of bacteria and fungi by investigating morphological and biochemical characteristics are laborious, time consuming and error prone. In contrast, microorganism profiling by MALDI-TOF mass spectrometry offers an attractive alternative for detecting bacteria and fungi in a fast, simple and robust way, even those which are problematic with the established methods. For the full paper, please see http://www.emagazinescreening.com/screen/

November 20, 2006--Bruker Daltonics' Director of Bioinformatics, Dr. Herbert Thiele, was interviewed by Biocompare for their Technology Spotlight "Mass Spectrometry Data Analysis." Important points include:

Herbert Thiele, director of bioinformatics at mass spectrometry manufacturer Bruker Daltonics, identified data heterogeneity as a significant data-analysis problem. Heterogeneous data is now a fact, Thiele said, whether you happen to be part of a large research consortium or a stand-alone laboratory. Different vendors and instruments produce data in different forms, and a mass spec software system must be able to archive and analyze all of them, he said.

Even if you only have one instrument and do one experiment per day, then you do seven per week and many more per year, Thiele said. A database solution is the only way to compare experiments from one another and to extract and gain knowledge based on experiments done in the past. Bruker Daltonics’ ProteinScape, he explained, combines the archival and analytical power to both cope with data heterogeneity and provide confidence in protein identification results.

Another issue Thiele cited is data portability the ability to transfer data from one application to another. ProteinScape is one of a number of applications that support the HUPO-PSI mzData standard, which enables seamless movement of protein mass spectrometry data between software systems http://psidev.sou.rceforge.net/ms

For the full text, please click here.

October 2006--Instrument Design and Technology published a Feature Story Bioinformatic Platform for Data Warehousing and Processing of Heterogeneous Data in Proteomics by Herbert Thiele, Jörg Glandorf Bruker Daltonics GmbH Gerhard Körting, Martin Blüggel Protagen AG Helmut E. Meyer, Christian Stephan Medizinisches Proteom-Center

October 8, 2006 -- Fox 23 News featured a Bruker AXS customer and their Bruker AXS instruments. Please go to http://www.fox23news.com/nanonow/, then choose any of the links under "video on demand". You will then be able to access a list of all the Nano Now clips. Choose "10-8-06 Segment 4 with Richard Matyi, CNSE"

October 6, 2006--Molecular and Cellular Proteomics published online an important methodologies paper entitled:

Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers

Richard R. Drake, E. Ellen Schwegler, Gunjan Malik, Jose Diaz, Timothy Block, Anand Mehta and O. John Semmes

From the Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia 23507 and Pennsylvania 18901

The application of mass spectrometry to identify disease biomarkers in clinical fluids like serum using high throughput protein expression profiling continues to evolve as technology development, clinical study design, and bioinformatics improve. Previous protein expression profiling studies have offered needed insight into issues of technical reproducibility, instrument calibration, sample preparation, study design, and supervised bioinformatic data analysis. In this overview, new strategies to increase the utility of protein expression profiling for clinical biomarker assay development are discussed with an emphasis on utilizing differential lectin-based glycoprotein capture and targeted immunoassays. The carbohydrate binding specificities of different lectins offer a biological affinity approach that complements existing mass spectrometer capabilities and retains automated throughput options. Specific examples using serum samples from prostate cancer and hepatocellular carcinoma subjects are provided along with suggested experimental strategies for integration of lectin-based methods into clinical fluid expression profiling strategies. Our example workflow incorporates the necessity of early validation in biomarker discovery using an immunoaffinity- based targeted analytical approach that integrates well with upstream discovery technologies.

To whom correspondence should be addressed: Dept. of Microbiology and Molecular Cell Biology, Lewis Hall 3144, Eastern Virginia Medical School, Norfolk, VA 23507. Tel.: 757-446-5904; Fax: 757-446-5766; E-mail: semmesoj@evms.edu

October 2006 --In its online-journal, "The Column", LC GC Europe features a new article about "Multi-targeting Pesticides" by Bruker Daltonics scientists. The application is based on the Bruker Daltonics micrOTOF mass spectrometer. Please follow this link

November 2006--A five minute video about Bruker Optics' IFS 120 Research FTIR spectrometer in use for high resolution atmospheric emission applications is available on www.youtube.com Just search for "Bruker".

Genome Technology, in an article "Proteomics: HUPO Brain Proteome Project Emerges from Pilot Phase," interviewed Bruker Daltonics Director of Bioinformatics, Dr. Herbert Thiele. Key points include that the HUman Proteome Organisation (HUPO) Brain Proteome Project (BPP) has adopted the use of Bruker Daltonics' ProteinScape, Bruker's centralized proteomics project management system for data warehousing and management. ProteinScape serves as a common software platform for the entire BPP community, thereby obviating the source of typical translation problems for data generated in different labs, Dr. Thiele says.

The platform can process data to be compatible with HUPO's PSI mzData standard, which enables all projects to be archived according to one common standard. Locally derived results can thus be transferred to a central standard managed at the Bochum, Germany's Medical Proteom-Center's data collection server, Dr. Thiele says. Once there, the processing of data is accomplished with the help of Bruker's ProteinExtractor, which Thiele says can generate lists of true, non-redundant proteins based on MS/MS searches.
October 2006

Science magazine presented the new Ibis T5000 universal biosystem system as its featured new product. The system can simultaneously identify thousands of types of infectious organisms in a sample without prior knowledge of what might be in the sample. It incorporates the Bruker Daltonics micrOTOF electrospray ionization time- of-flight mass spectrometer.
September 29, 2006

ACS' Analytical Chemistry published "MALDI-MS Direct Tissue Analysis of Proteins: Improving Signal Sensitivity Using Organic Treatments" by R. Lemaire, M. Wisztorski, A. Desmons, J. C. Tabet, R. Day, M. Salzet, and I. Fournier*

Laboratoire de Neuroimmunologie des Annélides, FRE CNRS 2933, Bât SN3, 1 er étage, Université des Sciences et Technologies de Lille, 59655 Villeneuve d'Ascq Cedex, France, Synthèse, Structure et Fonction de Molécules Bioactives, UMR-CNRS 7613, Boite 45, Université Pierre et Marie Curie, 4 place Jussieu, 75252 Paris Cedex 05, France, and Département de Pharmacologie, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec, J1H 5N4, Canada

Abstract:

Direct tissue analysis using MALDI-MS allows the generation of profiles while maintaining the integrity of the tissue, displaying cellular localizations and avoiding tedious extraction and purification steps. However, lower spectral quality can result from direct tissue analysis due to variations in section thickness, the nature of the tissue, and the limited access to peptides/proteins due to high lipid content. To improve signal sensitivity, we have developed a tissue-washing procedure using organic solvents traditionally used for lipid extraction, i.e., CHCl 3, hexane, toluene, acetone, and xylene. The increased detection for peptides/proteins ( m / z 5000-30 000) is close to 40% with chloroform or xylene, and 25% with hexane, while also improving sample reproducibility for each solvent used in the present study. This strategy improved matrix cocrystallization with tissue peptides/proteins and more importantly with cytoplasmic proteins without delocalization. The extracted lipids were characterized by nanoESI-QqTOF/MS/MS using the precursor ion mode, lithium adducts, or both and were identified as phospholipids including phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and lysophosphatidylinositol, confirming membrane lipid extraction from the tissues.

Web Release Date: September 15, 2006

American Biotechnology Laboratory printed a technical article entitled "Automated Cell-Type Specific Molecular Profiling by Imaging Mass Spectrometry". Recent advances in imaging mass spectrometry (IMS) include the application of MALDI mass spectrometry analysis to biological tissues to produce ion density maps of the sample surface. Imaging mass specrometry reveals the expression levels and spatial distributions of known and unknown compounds in complex tissues, regardless of their nature or molecular weights, with micrometer resolution and femtomolar sensitivity. Unlike other methods of tissue content analysis, IMS does not require tissue homogenization, protein extraction, compound labeling, radioisotypes, affinity tags, or expression markers. The article describes the IMS installation at Bruker Daltonics IMS partner Protein Discovery Inc. in Knoxville and their tissue imaging and profiling service laboratory. Recent developments: The popularity of imaging mass spectrometry is growing as researchers consider the advantages of imaging both large and small molecules without labels or radioisotopes, and without homogenizing or otherwise disturbing the spatial arrangement of mounted tissue slices. Recent publications cover topics such as the application of IMS to biomarker discovery and analysis of psychiatric disease, localization of small drug molecules in brain tissue, the depth of tissue from which imaging mass spectrometry tissue can be collected, and 3-D reconstruction of tissue slice ion density profiles. Current public imaging mass spectrometry projects include breast cancer biomarker discovery and the development of specialized bioinformatics tools for analyzing imaging mass spectrometry data.

American Biotechnology Laboratory also published a technical paper entitled "Peptide De Novo Sequencing with (Bruker Daltonics) MALDI-TOF/TOF: A Simple Approach Using Sulfonation Chemistry" by Paolo Conrotto and Ulf Hellman at the Ludwig Institute for Cancer Research in Uppsala, Sweden. A summary reads:

One of the main focuses of the scientific community, now that major advances have been achieved in the comprehension of genome organization, has become the study of proteins, including their structure and activities. Among the different techniques available, mass spectrometry has played a fundamental role and is experiencing rapid growth.¹ Matrix-assisted laser desorption ionization (MALDI) time- of-flight (TOF)/TOF instruments (Ultraflex Bruker Daltonics, Bremen, Germany), taking advantage of the reflectron mode, combine a soft ionization process with good sensitivity and resolution ²

Until recently, many proteomic projects were aimed at identifying proteins in biological samples in order to characterize the proteomic profile of subcellular compartments, cells, tissues, or pathological conditions. A deeper comprehension of the protein machinery will shed light on the complex and highly dynamic protein network (interactome), how this network transduces external stimuli inside the cell (signalosome), and how it regulates cellular processes (metabolome). Moreover, the identification of biomarkers for severe pathological conditions, such as cancer, heart disease, and neurodegenerative diseases, will allow the establishment of early diagnosis and the detection of pharmaceutical targets.

Experimentally, in peptide mass fingerprinting (PMF)³ proteins, after enzymatic digestion, are resolved in a number of peptides, whose masses are determined and matched with a sequence database. However, the presence of splicing variants in cells, combined with the generation of different protein isoforms or fusion proteins, gives rise to a complex picture that demands a more detailed analysis. Furthermore, the study of species with yet uncharacterized genomes or the investigation of post- translational modifications (PTMs) is not possible with classical PMF, requiring simple, reliable de novo sequencing. In the last 5-7 years, much effort has been expended in order to improve the performance of peptide sequencing with MALDI- TOF instruments.

The New York Times,in a lengthy article entitled "Counterfeit drugs imperil health and profits" writes in part:

MOSCOW-- Counterfeit prescription drugs are proliferating in Russia, and indeed, in many countries. Russians are doing a very good job, experts say, cutting into the profits of pharmaceutical companies that are trying to tap growing demand inside Russia.

Experts say fake drugs are being smuggled to Europe and the United States, the world's most lucrative prescription drug market. Drug counterfeiting is different from the production of low-cost medicines. The variety of fakes range from a crude mix of glue, chalk and sugar to nearly exact chemical replicas of complex pharmaceuticals, like Pfizer's Lipitor or the anti- impotence pill Viagra, both of which have been the targets of anti- counterfeiting prosecutions in Moscow.

Counterfeiters operate in India, China and elsewhere; Russia's underground prescription medicine market is distinguished for being at the forefront of a new trend of exceedingly high quality fakes. Indeed, private investigators from Pfizer surveying the Russian market found fakes of exceptional quality - by the company's own admission.

Counterfeit prescription drug smuggling is on the rise; agents opened 58 cases in 2004, up from 30 the previous year. The World Health Organization has estimated that counterfeiting pharmaceuticals, on a global basis, is a $32 billion business.

The best counterfeits are made at legitimate plants, which might run an extra night shift to make fakes. Detectives tracing the trail of counterfeit Cavinton that turned up in a Moscow hospital were led to a Moscow warehouse registered to Tatyana Bryntsalova, the wife of Vladimir Bryntsalov, a pharmaceutical magnate who ran as a dark horse candidate for president of Russia in 2004, according to police records.

Meanwhile, the growing proliferation of fake drug supplies around the world as led the FDA to consider an expensive new radio tagging system for tracking prescription medicine in the United States. The system, now in a trial phase, is considered the most significant change in drug packaging since tamper-proofing was developed in the 1980s.

In a laboratory off Moscow's traffic- clogged Leninsky Avenue, Leonid Mikhalitsyn, a physicist, stands at the industry's front line against fakes. As a spectrograph operator for the German scientific instrument maker Bruker, he works in an ultra-modern, glass-enclosed office. The spectrograph somewhat resembles a desktop PC with a round, pill-sized scanner built into the top. The $80,000 machine is the gold standard for spotting copycat medicine.

On a recent morning, Mikhalitsyn was testing Biseptol, the Russian trade name for a Polish-made antibiotic marketed in the United States as Bactrim. Mikhalitsyn said the fake Biseptol is nearly impossible for a doctor or patient to tell from the real one, and would work just as well.

On a Formica counter in Mikhalitsyn's lab lay a Ziploc bag of tiny ampoules, along with stamps and labels certifying quality. The bags contained fake Cavinton found at the Moscow warehouse, from the same batch shipped to Merkeshkin's hospital.

After three minutes of examination, Mikhalitsyn had his answer.

"It's a fake," he said, pointing to a red graph on his monitor depicting the chemical makeup of the pill. The computer screen displayed the readout from a genuine pill. The two lines were nearly overlapping, which meant the chemicals were close to identical, Mikhalitsyn said.

"They are either short one ingredient or have added an additional ingredient," he said. "It's really no different from the original."

www.iht.com/articles/2006/09/04/business/fake.php
September 4, 2006,

Genetic Engineering News interviewed Bruker AXS senior applications scientist Cary Bauer as part of their article "Protein Crystallization in Pharma Research." Important points include, "We recently introduced the Crystal Farm Imaging System as a means of getting in and automating the whole process of protein crystallization from start to finish." The Crystal Farm imaging system automates protein crystallization by integrating incubation at chosen temperatures together with optical imaging of the crystal growth plates at prescheduled intervals. This accelerates the process of growing diffraction-quality protein crystals. Crystals harvested from the Crystal Farm are then characterized using a Bruker AXS Proteum x-ray system.

For high-throughput applications, this includes the latest high-brilliance Microstar x- ray source and a highly sensitive and fast readout Proteum CCD detector, as well as a BruNo robotic sample handler, Bauer explains. The system is driven by the Proteum software suite, which contains new modules for determining crystal quality. The Proteum suite provides a simple, robust interface for automated screening and data collection.....
September 1, 2006

Science magazine in their supplement "Mass Spectrometry in Drug Discovery and Development: from Physics to Pharma" includes an interview with Bruker Daltonics Assistant Vice President Victor Fursey. Highlights include Fursey's comments: "You see mass spectrometry in everything from new chemical entities to formula determination to target profiling and preclinical work. Now, you can even see it at the far end, in manufacturing. And many researchers are working to bring mass spectrometry into diagnostics."

Fursey of Bruker Daltonics highlights an emerging field facilitated by MS. "Metabolomics is gaining a lot of momentum in the effort to understand the pharmaceutical world," he says. "Much of what's going on in metabolomics stems from nuclear magnetic resonance (NMR) technology. We're finding that mass spectrometric data can be very complementary to NMR." His company and Bruker BioSpin offer the Metabolic Profiler, an integrated platform for metabolic studies and analyzing complex mixtures. It features an HPLC-microTOF ESI-TOF system and an optional Avance NMR spectrometer and integrated software for data acquisition, evaluation, and statistical analysis in such applications as assessing the metabolic profile of a living organism to distinguish between normal and altered states and studying the mechanism of drug-induced toxicity. Fursey notes that the Metabolic Profiler is fully integrated into the Bruker Compass OA software environment.
September 1, 2006

Sequenom, Inc. announced today that City of Hope National Medical Center (City of Hope) has purchased Sequenom's MassARRAY genetic analysis system and portfolio of application tools for the Center's molecular marker research and individualized cancer care initiatives.

"We will utilize Sequenom's platform and applications for quantitative gene expression and methylation (epigenetic) studies. In addition, we will use the high throughput genotyping application as an integral part of our on-going research both to identify individuals at high risk for developing cancer, and to aid in the development of therapeutic modalities based on the unique genetic profile of a given patient," said Garry Larson, Ph.D., Associate Research Scientist, City of Hope. "The MassARRAY platform is unique and particularly well-suited to our needs because it enables us to perform many different types of analysis in a cost- effective manner and on a single platform."

The National Cancer Institute has designated City of Hope a 'Comprehensive Cancer Center,' one of just a handful of such elite institutions nationwide, and we are excited that their researchers will use the MassARRAY platform for their pioneering cancer studies involving epigenetics," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "Epigenetic analysis has significant clinical potential in cancer research and other fields. Our MassARRAY technology enables this important analysis and will help accelerate advancements in understanding and potentially treating cancer and other diseases."
July 19, 2006

Nature Methods announced their publishing of a new Bruker Daltonics application note on their website: Fast and reliable MALDI-TOF MS-based microorganism identification Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) fingerprinting is a fast and reliable method for the classification and identification of microorganisms, with applications in clinical diagnostics, environmental and taxonomical research, or food-processing quality control.

http://info.nature.com/cgi-bin24/DM/y/eY6G0E6UKf0A05b70Ez
July 17, 2006

The East African Standard (Nairobi, Kenya) published an article "Kenya: Low-Cost Infrared Device May Save Farmers Millions," describing how scientists at the World Agroforestry Centre (Icraf), Gigiri, in cooperation with private sector researchers at Analytical Spectral Devices of the United States and a German company, Bruker Optik, have developed a new technology that uses infrared light to assess soils for various parameters. The ground-breaking technology, known as infrared spectroscopy or infrared diagnostics, is simple, fast, cheap and reliable. In addition to the analysis, it gives recommendations on how to improve depleted soils and boost agricultural productivity, said Dr. Keith Shepherd, the Principal Soil Scientist at the World Agroforestry Centre, Nairobi....The new technique allows researchers to achieve two things that were not previously practical. First, it allows soil scientists to use the type of diagnostic surveillance approaches to those used in medicine by providing a tool for rapid screening of soil health. Second, it allows them to rapidly map soil degradation and constraints, in combination with geo-referencing and satellite imagery. The World Bank is using the technology in an assessment and monitoring of soil degradation in Western Kenya in an initiative to halt land degradation and restore thousands of hectares of degraded farmland. The Bank is also using the technology to establish a carbon baseline for trading purposes.

http://www.cgiar.org/monthlystory/feb2006.html
Click here for link
July 3, 2006

ProteoMonitor face=verdana,arial interviewed Bruker Daltonics' Executive Vice President, Dr. Michael Schubert, for its regular "Proteomics Pioneer" feature. "Michael Schubert has been involved in the development of ion trap mass spectrometers at Bruker for more than 15 years."

Dr. Schubert disclosed that Bruker Daltonics' use of nonlinear resonance ejection with phase coupling is the key reason for its ion trap performance leadership in terms of scan speed and mass range, while providing the best available ion capacity and sensitivity. He also disclosed that Bruker's high- capacity trap design, which can trap both positive and negative charges at the same time, is particularly well suited to do electron transfer dissociation (ETD). This is important because ETD is a process where positively and negatively charged ions are brought together to effect the dissociation. Scientists have found it is rather difficult to implement ETD on alternative, lower-performance ion trap designs, Dr. Schubert explained.
June 22, 2006
For more information on ETD, please see Dr. Schubert's (4:37 minute) live interview from Pittcon 2006.

TASS Medical News covered the announcement that Bruker Daltonics has received official Russian Medical Device Registration for all its Flex-Series MALDI-TOF Mass Spectrometers.
April 25, 2006

Drug Discovery News, in its article "Cataloging Microbes", writes about the newly-announced Bruker Daltonics collaboration with the national German Collection of Microorganisms and Cell Cultures (DSMZ) to identify and classify microbes from their proteomic profiles. The work will combine Bruker Daltonik's technical expertise and its new MALDI BioTyper system, which it introduced in March at Pittcon 2006 in Orlando, with the DSMZ's vast repository of biological samples.
"Bruker Daltonik has the expertise in the instrumentation, the sample preparation and the data interpretation using sophisticated pattern matching approaches," says Dr. Wolfgang Pusch, director of clinical proteomics and biomarker analysis at Bruker Daltonik. "However, we did not have the expertise in microbiology or access to broad strain collections covering considerable parts of the taxonomical kingdoms of bacteria, archae, yeasts and fungi. So it made a lot of sense to approach the DSMZ."
April 2006

American Biotechnology Laboratory published a paper by John Hopkins University senior staff member Dr. Plamen Demirev entitled "Microorganism Identification by Mass Spectrometry-based Top-Down Proteomics." The research was performed with a Bruker Daltonics ultraflex MALDI-TOF/TOF mass spectrometer.
April 2006

Nature Methods published an application note by Bruker Daltonik scientists in Leipzig entitled Fast and Reliable MALDI-TOF MS-based microorganism identification: Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) fingerprinting is a fast and reliable method for the classification and identification of microorganisms, with applications in clinical diagnostics, environmental and taxonomical research, or food-processing quality control. The MALDI BioTyper MALDI-TOF MS fingerprinting system allows researchers to perform this process for the unambiguous identification of bacteria, yeasts, and fungi in minutes.
April 2006

The Wisconsin State Journal interviewed Bruker AXS Executive Vice President Roger Durst, Ph.D. in a detailed article entitled "X-ray firm Bruker AXS leads field."
March 26, 2006

Pittsburgh Conference Today reported today that the Bruker Group won more Pittcon Editors Awards for new products this week than any other organization. Bruker AXS won honorable mentions for its new D8 Screen Lab and its S8 Tiger XRF instrument. The privately-held Bruker BioSpin member of the group won an honorable mention for its 800 Mhz UltraShield Plus NMR instrument. See Bruker Daltonics' Live from Pittcon video.
March 16, 2006.

Clinical Laboratory International published a paper on the Bruker Daltonics CLINPROT solution by scientists at Bruker Daltonik, Bremen, the Technical University of Munich, and the Charite University Hospital, Berlin. It is entitled "Cutting edge technologies for the detection of protein biomarkers."
February/March 2006

PharmaAsia face=verdana,arial published an article entitled "Mass Spec and Metabolomics Are a Powerful Combination." The article includes a detailed description of the collaboration between the University of North Carolina and Bruker Daltonics with their new Bruker Daltonics 12 Tesla Fourier Transform mass spectrometer. UNC Assistant Professor Dr. Christoph Borchers is interviewed for the article.
Jan-Feb 2006

LCGC in "The Peak" published a paper by scientists in the Department of Forensic Medicine at the University of Helsinki:
"Forensic Drug Screening by LC-MS Using Accurate Mass Measurement."
Because of progress in liquid chromatography/time-of-flight mass spectrometry(LC/TOF-MS) instrumentation, data processing and reporting, the measurement of compounds' accurate mass is becoming routine practice in screening analysis based on target databases. As such databases of monoisotopic masses can be easily updated with recent data from the literature, rapid characterization of new compounds and metabolites is possible without the need for primary reference standards. This approach has already been established in comprehensive toxicological urine screening and in analysis of drug-of-abuse in seized street drug samples. Currently, a mass accuracy of 5 ppm can be routinely achieved, and confirmation via a numerical isotopic pattern match (SigmaFit) is provided by a new generation LC/TOF-MS instrument.
January 2006

Biophotonics International published an article by Bruker Daltonics scientists entitled " Protein Analysis Moves into the Fast Lane," describing how MALDI-TOF mass spectrometry imaging improves biomarker research.
January 2006

Laboratory Equipment published an article by Bruker AXS Microanalysis entitled "Modern Energy Dispersive Spectrometers."
January 2006

Genetic Engineering News published a detailed article "Applying Biomarker Discovery Strategies" about the recent American Association of Clinical Chemistry proteomics conference in Washington. The large photograph accompanying the article is that of a Bruker Daltonics scientist operating the Bruker Daltonics ClinProtRobot workstation for fractionation and purification of complex samples. The comprehensive review summarizes presentations by leading proteomics scientists from the US, Canada, and Europe. The article starts off with:
Technologies, Tools, and Methodologies for Successful Validation and Clinical Development
"With the human proteome comprising 10 times more proteins than there are genes in the genome, the complexity of proteomics research and the efforts under way to identify and characterize protein biomarkers of disease and translate those findings into informative and reproducible diagnostic tests is driving the development of new technologies and improved methods for analyzing proteins in biological samples."
January 1, 2006

Clinical Chemistry published a paper by scientists at the Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany. The paper is entitled "Preanalytical Impact of Sample Handling on Proteome Profiling Experiments with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry." MALDI-TOF MS measurements were performed with an Autoflex II (Bruker Daltonics) operating in positive linear mode, using Bruker Daltonics AnchorChips.

BIOforum Europe published a paper entitled "Mass Spectrometric Large-Scale Proteome Analysis" by Bruker Daltonik scientist Dr. Ralf Ketterlinus. The abstract reads: Mass Spectrometers have become essential for the analysis of complex proteomes. Ion trap mass analyzers are advantageous in proteomics applications due to their high duty cycle for a combined MS and MS/MS analysis, allowing a successful protein identification by peptide fragmentation analysis. However, the detection of low abundant proteins is limited in highly complex samples by dynamic range and acquisition speed of the instrument. Thus proteins of particular interest may be lost.

Conclusion
The new HCTultra dramatically increases the number of identified proteins compared to the renowned HCTplus in any large-scale proteomics application. Outstanding detection rates of low abundant peptides and high sequence coverage of the entity of proteins is a result of the renowned excellent mass accuracy as well as remarkable improvements in speed and sensitivity in the HCTultra.

BIOforum Europe also published a paper in the same issue entitled "Bioinformatic Strategies and Concepts in Proteomics by Bruker Daltonik scientist Dr. Herbert Thiele, Director Bioinformatics. The abstract reads: The tremendous amounts of data from today's expression proteome analysis require a database solution with sophisticated warehousing and data mining strategies. ProteinScape (Bruker Daltonics) provides a bioinformatics platform for in-house proteome studies as well as for large scale approaches, like the human brain proteome project (HUPO BPP). Data from 1D/2D PAGE with over 10,000 spots by MALDI-MS (MS/MS) and multi- dim LC (over 2 Mio. ESI LC-MS/MS spectra) are archived. This is the starting point for the development of new algorithms and strategies for handling and processing large data sets to identify and characterize proteins.
December 2005

The International Journal of Cancer published an "early detection and diagnosis" paper by German scientists, including Bruker Daltonics' Dr. Katrin Sparbier. It is entitled "Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients."
The scientists investigated the expression pattern of the breast cancer associated gene LIV-1 on mRNA and protein level in 111 human breast cancer patients by in situ hybridization as well as immunohistochemistry and focused on the unknown potential of LIV-1 expression levels as a prognostic marker. To their knowledge, this is the first study on endogenous LIV-1 protein expression. Results of the study indicate that LIV-1 mRNA and protein expression levels are only weakly correlated, suggesting posttranscriptional regulatory mechanisms. Furthermore, LIV- 1 mRNA quantity in combination with a positive ER status seem to represent a better marker than the progesterone receptor status according to the prognostic significance for relapse free survival (RFS). A negative correlation of LIV-1 protein levels with tumor size, grade and stage reflects an association of LIV-1 protein expression with less aggressive tumors. High LIV-1 protein expression seems to be associated with a longer relapse free and overall survival in breast cancer patients with invasive ductal carcinoma. This association, however, seems to be dependent from other prognostic markers. Their data suggest that LIV-1 is a promising candidate for a novel marker for breast cancer patients with better outcome. Furthermore, their study presents a revised cDNA sequence of LIV-1 and demonstrates the localization of endogenous LIV-1 in the endoplasmic reticulum. (Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020- 7136/suppmat/index.html).
© 2005 Wiley-Liss, Inc. Volume 117, Issue 6, Pages: 961-973
December, 2005

The Journal of Biomolecular Techniques published a paper by Bruker Daltonik Leipzig scientists entitled " Selective Isolation of Glycoproteins and Glycopeptides for MALDI-TOF MS Detection Supported by Magnetic Particles." Glycosylation is the most common form of posttranslational modification of proteins (50-80%). The isolation, discovery, and subsequent identification of glycosylated peptides and proteins is becoming more and more important in glycoproteomics and diagnosis. MALDI-TOF mass spectrometry is an ideal technique for identifying peptides and proteins and their corresponding modifications...
December 2005

LCGC Europe face=verdana,arial published an application note by scientists at Bruker Daltonics and the University of Tuebingen Institute of Pharmacy entitled Identification of Urinary Nucleosides by ESI-TOF-MS. The novel method describes the value of true isotopic pattern in conjunction with accurate mass for structural assignment of known and unknown nucleosides from urine samples. Modified nucleosides are elevated in cancer patients' urine because of the up-regulated metabolism and cell growth in tumour tissue and thus increased RNA turnover. These observations have formed the basis for further investigations of nucleosides as potential tumour markers in cancer diagnosis.
December 2005

BIOForum Europe published a "Product Focus Spectrometer" article entitled "Mass Spectrometric Large-Scale Proteome Analysis," describing research done with the Bruker Daltonics HCTultra ion trap. "Mass spectrometers have become essential for the analysis of complex proteomes. Ion trap mass analysers are advantageous in proteomics applications due to their high duty cycle for a combined MS and MS/MS analysis, allowing successful protein identification by peptide fragmentation analysis. However, the detection of low-abundant proteins is limited in highly complex samples by dynamic range and acquisition speed of the instrument. Thus proteins of particular interest may be lost...The new HCTultra ion trap dramatically increases the number of identified proteins compared to the renowned HCTplus in any large-scale proteomics application. Outstanding detection rates of low-abundant peptides and high sequence coverage of the entity of proteins are a result of the renowned mass accuracy as well as remarkable improvements in speed and sensitivity in the HCTultra."
November 2005

Science magazine published a paper entitled "Fluorescent Guest Molecules Report Ordered Inner Phase of Host Capsules in Solution" by scientists at the University of Missouri-Columbia's Department of Chemistry. X-ray data were collected on a Bruker AXS SMART 1000 charge-coupled device diffractometer. Despite recent strides in the synthesis of elaborate nanometer-scale molecular hosts, the internal structure of these self-assembled cages remains ill characterized. The scientists used fluorescent probe molecules, pyrene butyric acid (PBA), as guests in C-hexylpyrogallol arene capsules to relay information about the chemical environment on the interior of the assemblies. Spectroscopic and single-crystal x-ray diffraction studies show that, in both solution and the solid state, the host can encapsulate two PBA guests and keep them well separated through specific interactions with the capsule walls.
September 23, 2005

The William & Mary News published an article entitled "Chemistry departments' X-ray diffractometer expands opportunities for undergraduates." When chemistry students returned to campus this fall, they saw something new”an X-ray diffractometer that was installed in Rogers Hall. The diffractometer is a common enough instrument in postgraduate programs, but the College joins a group of perhaps a dozen undergraduate-oriented programs having such state-of-the-art instrumentation on-site. Professor Robert Pike is the director of the chemistry departments new X-Ray Crystallography Center. The diffractometer, funded by a grant from the National Science Foundation, is the heart of the center. Having a diffractometer in Rogers Hall not only increases the research capabilities of the department but also increases the value of a chemistry degree from William and Mary...
September 22, 2005

Genetic Engineering News interviewed Bruker Daltonics' Director of Proteomics Systems, Dr. Catherine Stacey, for their detailed front page story "Applying Mass Spec Tools in Proteomics." Dr. Stacey described the company's new HCTultra PTM discovery system. In addition, the extensive article addressed the Bruker Daltonics ClinProt solutions for biomarker discovery, validation, and identification.
See front page picture.
September 15, 2005.

LCGC Magazine face=verdana,arial included the new Bruker Daltonics Application Note "New Approach for Characterization of Post-Translationally Modified Peptides Using Ion Trap MS with Combined ETD-CID Fragmentation" in their Application Notebook. Bruker Daltonics authors are Ralf Hartmer and Markus Lubeck.
September 2005

DrugPlus International published a detailed paper by Bruker Daltonics scientists entitled "Protein profiling and identification in complex biological samples using LC-MALDI." Offline coupling of liquid chromatography (LC) to MALDI mass spectrometry (LC-MALDI) is a method for analysis of complex biological samples that is becoming more and more widely used. The increasing popularity of this technique is due to several reasons. First, the approach is relatively straightforward and secondly, once fractions are spotted on MALDI targets there are no time constraints on carrying out further analyses. This means that intelligent data dependent MS/MS analysis can be carried out on the basis of prior MS and MS/MS analysis, resulting in greater protein success identification rates. This article describes the LC-MALDI technique and illustrates its power through an example analysis involving the complex lysate of Corynebacterium glutamicum ATCC13032. 350 non-redundant proteins were clearly identified in the lysate.
September 2005

Genomics & Proteomics, in their detailed article "Mass Spec and Metabolomics Are a Powerful Combination" writes: The ultimate in precision and limit of detection for mass measurement in metabolomics is the Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer. A collaboration between scientists from Bruker Daltonics and the University of North Carolina (UNC), Chapel Hill, N.C., used a 12-tesla FT-ICR to analyze metabolites in human blood samples, in order to demonstrate the application of FT-ICR to metabolomics. Twelve teslas is the highest field strength magnet commercially available in an FT-ICR. Results from the experiment demonstrated that it is possible to separate several hundred metabolites with better than 0.5 ppm resolution (with an internal calibration standard.)......Christoph Borchers, PhD, of UNC-Chapel Hill, cites intense interest in FT-MS for metabolomics:
..."We started this last year, and there's so much interest. This is unbelievable." FT-ICR MS will emerge as a dominant analytical method for metabolomics studies, concludes Genomics & Proteomics. Mass spectrometry is a tool that has the potential to untangle the highly complex human (or mammalian) metabolome, which is estimated at approximately 3,000 compounds.
September 2005

The Journal of Comparative Neurology published a paper by University of Wisconsin scientists, along with Bruker Daltonics' Dr. Sergei Dikler, entitled "Mass spectrometric map of neuropeptide expression in Ascaris suum." A mass spectrometric method was used for the localization and sequence characterization of peptides in the nervous system of the parasitic nematode Ascaris suum. Mass spectrometric techniques utilizing MALDI-TOF, MALDI-TOF/TOF, and MALDI-FT instruments were combined with in situ chemical derivatization to examine the expression of known and putative neuropeptides in the A. suum nervous system. This first attempt at peptidomic characterization in A. suum mapped the expression of 39 neuropeptides, 17 of which are considered to be novel and whose expression has not been previously reported. These analyses also revealed that the peptide expression profile is unique to each nervous structure and that the majority of peptides observed belong to the RFamide family of neuropeptides. In addition, four new peptide sequences with a shared C-terminal PNFLRFamide motif are proposed based on in situ sequencing with mass spectrometry.
© 2005 Wiley- Liss, Inc. Volume 488, Issue 4, Pages: 396-413
August, 2005

The Wisconsin Capital Times, in its article "Homeland security pacts a boon to firms in state," wrote: While most major homeland security decisions are made in Washington, the process of ensuring our nation's safety extends far outside the Beltway. In fiscal 2003 and 2004, the Department of Homeland Security issued thousands of contracts to companies across the United States, including more than 60 Wisconsin businesses that received a total of nearly $15 million... During those two years, the biggest contract issued to a Madison-based company was a $402,000 deal with Bruker AXS. According to Bruker spokesman Uwe Preckwinkel, the money came from Customs and Border Security, a division of the Department of Homeland Security. It purchased a Bruker X- ray diffraction system, which can scan and identify the chemical structure of any substance. "Our equipment has a variety of applications," Preckwinkel said. "We've used it to tell the difference between a real and fake Rolex... and on engagement rings, to make sure the diamond is real." But Preckwinkel said customs officials were particularly interested in identifying suspicious powders - so he assumed early on that the Bruker equipment would be used for homeland security purposes.
August 27, 2005

In-Pharma Technologist covered the announcement Bruker AXS to Acquire X-ray Analysis Software Company SOCABIM, writing "X-ray diffraction has many applications in the pharmaceutical industry - from drug discovery, preformulation and formulation, through to manufacturing and quality assurance. In all of these areas, it can be used to determine the crystallographic constitution of the sample from which the physical properties of an active pharmaceutical ingredient (API) or an excipient can be derived. Meanwhile, X-ray Fluorescence is used in the pharmaceutical sector to detect inorganic contaminents in the production process. Both technologies are cited in the U.S. Food and Drug Administration's new initiative on Process Analytical Technology (PAT)."
August 17, 2005

ProteoMonitor face=verdana,arial , in their article "Leaders of Human Brain Proteome Project To Present Preliminary Protein Lists at HUPO, wrote: "With data collected from about a dozen pilot- phase laboratories, leaders of the Human Brain Proteome Project (HBPP) expect to present preliminary results of their project, in the form of protein lists, at the 4th annual HUman Proteome Organization (HUPO) congress scheduled to take place in Munich at the end of August." ProteoMonitor indicated: Data were returned by some 12 labs. In the HBPP, data were collected, stored, and submitted as mass spectrometry peak lists in Bruker Daltonics' ProteinScape data-collection software, instead of being submitted as protein lists after analysis by each individual laboratory. According to a scientist at Ruhr University in Germany, HBPP decided to use ProteinScape to store data for the HBPP because it is the only software that allows for the storage of 2-D gel, 1-D gel, 1-D liquid chromatography, and 2-D LC data. In addition, the software integrates well with each of the four different search engines, and it is easy to use and readily available as HTML/web-based software, he indicated.
August 8, 2005

Bruker BioSciences Reports 11.3% Revenue Growth and Improved Operating Income, Net Income and Operating Cash Flow for the Second Quarter 2005
August 3, 2005

Drug Discovery News discussed the collaboration between Bruker Daltonics and Melbourne-based HealthLinx Pty. Ltd in their Global News article "ClinProt Chosen for Cancer Biomarker Discovery."

The collaboration focuses on technology transfer and cooperation between the two firms to develop disease-specific assays for use in in-vitro diagnostic (IVD) research and clinical trials using Bruker Daltonics’ ClinProt platform technology for clinical proteomics.
August 2005

The Indiana Tribune-Star reported on a new Bruker AXS D8 X-ray diffraction instrument being installed at the Rose-Hulman Institute of Technology in Terre Haute. It is to be used by physics and optical engineering students and faculty to examine the molecular composition of materials. "The Bruker D8 Focus X-ray diffraction machine will provide students and faculty access to a modern research tool. The XRD machine has many functions and will be used in a variety of classes, outreach activities and research."
July 27, 2005

Prenatal Diagnosis published a paper by Taiwan and Northwestern University scientists, including Bruker Daltonics Taiwan's Shih-Hua Teng, entitled "Rapid detection of fetal aneuploidy using proteomics approaches on amniotic fluid supernatant."
Objective Conventional chromosomal studies or fluorescent in situ hybridization takes days to diagnose fetal aneuploidies during amniocentesis. Here, we evaluated the value of mass spectrometry-based clinical proteomics analysis on amniotic fluid supernatant (AFS) as a rapid detection of fetal aneuploidies.
Methods Proteomics profiles generated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) after fractionating samples with functionalized magnetic beads were used for differentiating 60 normal karyotypic from 20 aneuploid AFS. After the discriminating models were generated using genetic algorithm, we evaluated the clinical efficacy of the models in detecting aneuploidies in two batches (each n = 30) of AFS prior to the release of chromosomal diagnoses.
Results Within hours, the two-step proteomics analysis of AFS with the C18 model, followed by the weak cation exchange model, was able to detect aneuploid AFS at 3.3% disease prevalence rate with 100% sensitivity, 72 to 96% specificity, 11 to 50% positive predictive value, and 100% negative predictive value.
Conclusion Clinical proteomics analysis of AFS using magnetic beads- based sample preparation and MALDI-TOF-MS can be used as a rapid detection for fetal aneuploidies. With perfect sensitivity and negative predictive value of the two-step proteomics method, it may be used for rapid detection of aneuploid AFS immediately after amniocentesis. Further large- scale examinations are apparently needed to verify the clinical value of this rapid detection.
Copyright © 2005 John Wiley & Sons, Ltd. Volume 25, Issue 7, Pages: 559-566
July, 2005

DrugPlus International published a paper by Bruker AXS scientist Dr. Dan Frankel entitled "Structure based drug design and high throughput protein crystallization." Dr. Frankel indicates that there is an increasing need for the determination of protein structures by X-ray crystallography. Automated systems for the monitoring of crystal growth and subsequent handling of crystals greatly improve the efficiency of the process, he points out. (Reprints are available.)
July 2005.

Bruker AXS Wins Prestigious R&D 100 Award For Innovative VANTEC(TM)-2000 X-ray Detector Used in Materials Science Research
July 18, 2005

face=verdana,arial color=#0000a0 Biotechniques, the international journal of life science methods, published a research report by Argonne National Laboratory scientists entitled "Analysis of protein interaction and function with a 3-d MALDI-MS protein array." Research was performed using a Bruker Daltonics MALDI-TOF mass spectrometer.
July 2005

face=verdana,arial color=#0000a0 SpectrocopyNow.com's "What's New in Proteomics" newsletter published a recent scientific paper by University of Leipzig scientists entitled "Proteome analysis of Escherichia coli using HPLC and FT-ICR MS." FT-ICR MS is rapidly gaining popularity for proteome analysis as it provides high resolution, excellent mass accuracy, high sensitivity, and a high dynamic range, which makes it uniquely suitable for analyzing complex mixtures. The research was conducted using a nanoHPLC system coupled to a Bruker Daltonics 7 Tesla FTMS.
July 2005

Materials Engineering News contains an article in its Materials Characterization section entitled "Bruker AXS launches Its New XRD2 Solutions for Materials Research."... "The new XRD2 methodology represents a powerful solution for demanding applications in materials research, high-throughput screening, nanotechnology and thin-film research......"
Premier Issue

Wisconsin Ag Connection in their article "UW-Madison Gets Funds For Protein Study" reported that researchers at the Center for Eukaryotic Structural Genomics, based at the University of Wisconsin-Madison, have received a $20 million award to fund Phase II of the Protein Structure Initiative over the next five years. Information from the PSI project, funded by the National Institute of General Medical Sciences, will deepen our understanding of a variety of biological processes. Proteins are everywhere - nearly everything in a living system is protein-mediated. The PSI studies how the information in a gene is turned into a physical protein that does the work in a cell. The three-dimensional structure of each protein determines its function in an organism. PSI centers explore and define these 3-D structures and expand on this knowledge in a systematic way. ....The award will support about 30 positions at the UW- Madison. It will also lead to collaborations with local high-tech companies and researchers, including Promega, Bruker AXS, and stem cell researcher Jamie Thomson.
July 7, 2005

Science magazine, in their Milestones in Science section, included a discussion about the new Bruker Daltonics Prespotted AnchorChip(TM):
The disposable Prespotted AnchorChip--a matrix assisted laser desorption/ionization time of flight (MALDI-TOF) target--from Bruker Daltonics can help researchers find new lead compounds or biomarkers. According to Detlev Suckau, head of application development for MALDI-TOF instruments and proteomics at Bruker Daltonics, "This chip provides a 10-fold to 100-fold increase in sensitivity. It consists of a plastic substrate--developed by Eppendorf and Bruker Daltonics--with prespotted MALDI matrix and calibrant spots. Suckau says, "Eppendorf has the technical expertise to produce injection molded plastic chips of the required quality for this product. So it was an excellent choice to work with them."
July 1, 2005.

Drug Discovery News reported "Bruker, Healthlinx team up--ClinProt chosen for in vitro diagnostic research and clinical trials" on their front page, with the full story inside.
June 2005

face=verdana,arial color=#0000a0 ProteinCrystallography.com's Newsletter contains an interview with Bruker AXS scientists Sue Byram and Dan Frankel about the new MICROSTAR-H ultra-bright X-ray source and the new CrystalFarm™ for crystal growth automation--allowing scientists to get better crytals faster.
June 29, 2005

CrystalNews face=verdana,arial covered the announcement of Bruker AXS' Novel Protein Crystal Screening System.
June 29, 2005

Bio-IT World's Fully Equipped covered selected Bruker Daltonics ASMS press releases in their current issue:
Bruker Daltonics Inc. also addressed the issue of sample enrichment with the expansion of its ClinProt sample prefractionation technology. ClinProt uses magnetic beads with functionalized surfaces that capture and enrich proteins and peptides for analysis on Bruker Daltonics' AnchorChip. The assays include various types of bead, including hydrophobic beads, weak anion exchange and weak cation exchange beads, immobilized metal affinity capture beads, as well as antibody-based beads that specifically enrich particular clinical antigens. The portfolio of beads has now been further expanded with capabilities to address the analysis of large proteins and glycoproteins and antigen-specific enrichment of selected biomarker molecules. Samples are then analyzed using high-performance matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry.

The "large-protein beads" are designed to overcome previous limitations of biomarker discovery to peptide and small proteins and to exploit a mass range of up to several hundred kilodaltons. The large-protein beads are complemented by a new DHAP matrix that is optimized for high-molecular-weight proteins. The profiling of glycosylated peptides or proteins or of selected glycan structures can be informative in cancer research and diagnostics, as many tumor cells show altered glycans on their surface. The new Glyco-beads include chemical capture or lectin capture strategies. The "antibody-capture beads" enrich for specific antigens, thus enhancing access to specific low-abundance proteins in plasma.

Software Salutations
Several new software packages for analysis of mass spectrometry data were also presented at the meeting. Bruker Daltonics' new ProfileAnalysis 1.0 software further expands the use of electrospray ionization time-of-flight (ESI-TOF) mass spectrometry for clinical research and pharmaceutical development applications. ProfileAnalysis software is suited for small-molecule profiling of complex biological fluids such as urine.
June 20, 2005

Biocompare's Proteomics Newsletter included an interview with Bruker Daltonics scientist Christian Neusuess in their article "Analysis of Glycoproteins":

While analyzing free glycans can provide useful information, analyzing intact proteins is necessary for pharmaceutical quality control applications, says Christian Neusuess of Bruker Daltonics, who adds that electrospray ionization mass spectrometry is the ideal technique to use in such cases because of its high resolution. However, very complex glycoproteins are hard to analyze in this way. “If you have a glycoprotein which contains more than a couple of glycan structures, then … direct electrospray is not possible to resolve all the possible structures because of overlapping peaks of the different isoforms,” says Neusuess. The various glycoforms in a sample must be separated prior to analysis to simplify the mass spectrum, but to date this has been difficult because many of the electrolytes used in capillary electrophoresis-based separations of glycoproteins are not mass spec compatible. Neusuess and colleagues recently developed a new separation protocol—one that does not use NH3 as an electrolyte—that is compatible with mass spectrometry; the researchers were able to identify more than 130 different glycoforms of human erythropoietin.1

face=verdana,arial size=1>1. C. Neuseuss et al., “Glycoform characterization of intact erythropoietin by capillary electrophoresis- electrospray-time of flight-mass spectrometry,” Electrophoresis, 26:1442-50, 2005.
June 20, 2005

Genetic Engineering News interviewed Bruker AXS' Chief Technology Officer, Roger Durst, Ph.D., at length for their big article "Research Options for Structural Proteomics." Dr. Durst pointed out that standalone lab systems, like the MicroStar-H rotating anode generator from Bruker AXS, let researchers perform much or all of the crystallography work (that previously required traveling to a synchrotron beam line facility) in their own labs, saving time and money. "The MicroStar-H delivers x-ray intensities comparable to those of a second-generation synchrotron generator," he said--an order of magnitude increase when compared to previous models....Dr. Durst also discussed the new, high-sensitivity detector called "Platinum(TM)", which regulates the x-ray spectra path....It is more sensitive than an image plate detector by "about a factor of eight," Dr. Durst says. He concluded by describing the new Bruker AXS Life Science Laboratory for protein crystallization and macromolecular structure determination in Delft, the Netherlands.
June 15, 2005

The American Chemical Society's Chemical and Engineering Newsface=verdana,arial published a picture of Bruker AXS's new X8 PROSPECTOR and a paragraph about it, plus the new Bruker Daltonics ETD for the HCTultra ion trap mass spectrometer. The headline reads "New tools to screen proteins". See page 29 in the 'Inside Instrumentation' section.
June 13, 2005

LabPlus International published a paper by Bruker Daltonics scientists entitled, "A software solution for MALDI-TOF analysis of expression patterns in tissue." MALDI-TOF imaging of tissue samples allows visualization of the distribution of biomarkers in tissue.
June 2005

GIT Laboratory Journal Europe Editor Dr. Katja Habermueller interviewed Bruker Daltonics' President & CEO, Frank Laukien, Ph.D., in their Pittcon Highlights section. The two page interview is entitled, "Analytical Tools for PHARMA and LIFE SCIENCES," where she started off by pointing out that Bruker Daltonics and Bruker AXS "launched a row of interesting new products at Pittcon 2005." In response to her question, Dr. Laukien said, "We have some completely new technology that we introduced on the X-ray side at Bruker AXS- the new Vantec detector based on the patented Micro-Gap technology. From the technological point of view that is the most revolutionary release here at Pittcon and this new detector technology will show up on all kinds of X-ray instruments. But if I have to pick out one particularly compelling new product, I think it is the micrOTOF-Q. This high performance benchtop quadrupole time-of-flight mass spectrometer is not only a significant improvement, but it really changes the way the market operates. I think it really is going to have an effect on the dynamic of this market segment."

Biotechniques face=verdana,arial published a four page paper by Bruker Daltonics scientists and scientists at the Chang Gung Memorial Hospital in Taiwan entitled, "Fishing for Biomarkers: analyzing mass spectrometry data with the new ClinProTools software"
June 2005

The Eagle-Tribune interviewed Bruker Daltonics NBC Detection Corp. vice president Frank Thibodeau about the company's RAID-M handheld chemical agent detector.
May 28, 2005

Nature Biotechnology Magazine reports research by Novartis Research Foundation scientists in San Diego entitled "Enrichment and analysis of peptide subsets using fluorous affinity tags and mass spectrometry." The scientists introduced the concept of "fluorous proteomics," whereby specific peptide subsets from samples of biological origen are tagged with perfluorinated moieties and subsequently enriched by solid-phase extraction over a fluorous-functionalized stationary phase. MALDI-TOF analysis was performed with a Bruker Daltonics mass spectrometer operated in the positive ion mode. Peptides were deposited onto MALDI targets using the dried droplet method.
April 2005

Proteomics face=verdana,arial published an article by UK scientists entitled "C-terminal sequencing by mass spectrometry: Application to gelatine-derived proline-rich peptides." Protonated peptides derived from proline-rich proteins (PRP) are often difficult to sequence by standard collision-induced dissociation (CID) mass spectrometry (MS) due to preferential amide bond cleavage N-terminal to proline. In connection with bovine spongiform encephalopathy regulations, proteolytic products derived from the PRP collagen have been suggested as markers for contamination of animal feedstuffs with processed animal protein (Fernandez Ocaña, M. et al., Analyst 2004, 129, 111-115). Herein, the scientists report the identification of these marker peptides using the strategy of C-terminal sequencing by CID MS from their sodium and lithium adducts. Upon fragmentation a new cationized peptide was produced that is one C- terminal amino acid shorter in length. This dissociation pathway allowed for the facile identification of the C-terminal residue by matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry. Each newly formed cationized peptide was further fragmented by up to seven stages of electrospray ionization ion trap MS. Proline-rich C-terminal sequence tags were established which permitted successful database identification of collagen alpha type I proteins.
Volume 5, Issue 5, Date: No. 5, Pages: 1209-1216
April 2005

Chemical & Engineering News interviewed Bruker BioSciences' Chairman, President, and CEO, Dr. Frank Laukien, Ph.D., in their current issue. An important part of the interview included discussions of all the new Bruker products just announced at the Pittcon conference.
March 28, 2005

The ACS' Chemical and Engineering News wrote, "According to Assistant Professor of Chemistry Neil L. Kelleher of the University of Illinois, Urbana-Champaign, the dual ESI/MALDI (ESI/matrix-assisted laser desorption ionization) ion source for Bruker Daltonics' ultrOTOF- Q time-of-flight mass spectrometer was another significant introduction at this year's Pittcon. The dual source combines the company's new Apollo II ion-funnel ESI source with its existing ScoutMTP vacuum- MALDI ion source. The system "allows quick switching between ESI and MALDI," Kelleher said. "In other MS systems, it's necessary to physically remove one source and bolt on another to switch from ESI to MALDI or vice versa, which is a pain. The dual source also allows simultaneous introduction of ESI and MALDI ions," making it possible to internally calibrate TOF mass spectra to enhance mass accuracy."
March 28, 2005

The CDC's Emerging Infectious Disease publication covered the use of a Bruker Apex ESI-FTICR-MS (with a 7 Tesla superconducting magnet) by Isis Pharmaceutical's Ibis division in one of their studies. Ibis scientists described a new approach for infectious disease surveillance that facilitates rapid identification of known and emerging pathogens. The process uses broad-range polymerase chain reaction (PCR) to amplify nucleic acid targets from large groupings of organisms, electrospray ionization mass spectrometry for accurate mass measurements of PCR products, and base composition signature analysis to identify organisms in a sample.

All aspects of pulse sequence control and data acquisition were performed on a 1.1 GHz Pentium II data station running Bruker's Xmass software (Bruker Daltonics). Inputs to the signal processor are the raw mass spectra for each of the parallel PCR reactions used to analyze a single sample. The ICR-2LS software package was used to deconvolute the mass spectra and calculate the mass of the monoisotopic species using an "averagine" fitting routine modified for DNA (Drader et al., unpub. data). Using this approach, monoisotopic molecular weights were calculated. The spectral signals were algorithmically processed to yield base composition data as described previously. The amplitudes of the spectra are calibrated to indicate the number of molecules detected in the mass spectrometer versus m/z and the m/z values are corrected by using internal mass standards. The algorithm computes the organism's identity and abundances consistent with observations over all the PCR reactions run on the input sample.
March 2005

Rapid Communications in Mass Spectrometry published a paper by scientists at Texas State University entitled "Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of 4-sulfophenyl isothiocyanate-derivatized peptides on AnchorChipTM sample supports using the sodium-tolerant matrix 2,4,6-trihydroxyacetophenone and diammonium citrate". The reagent 4- sulfophenyl isothiocyanate (SPITC) is an effective, stable, and inexpensive alternative to commercially available reagents used in the N-terminal sulfonation of peptides for enhanced postsource decay (PSD) in matrix- assisted laser desorption/ionization time-of-flight mass spectrometric (MALDI-TOFMS) analyses. However, suppression of ionization of sulfonated peptides due to sample and matrix contaminants such as sodium can be a problem when using prestructured MALDI target sample supports, such as the Bruker Daltonics AnchorChipTM. The scientists show that use of the salt-tolerant matrix 2,4,6-trihydroxyacetophenone containing diammonium citrate (THAP/DAC) as an alternative to alpha- cyanohydroxycinnamic acid (HCCA) reduces the need for extensive washing of ZipTip-bound peptides or additional on-target sample clean-up steps. Use of the THAP/DAC matrix results in selective ionization of sulfonated peptides with greater peptide coverage, as well as detection of higher mass derivatized peptides, than was observed for HCCA or THAP alone. The THAP/DAC matrix is quite tolerant of sodium contamination, with SPITC- peptides detectable in preparations containing up to 50 mM NaCl. In addition, THAP/DAC matrix was found to promote efficient PSD fragmentation of sulfonated peptides. The scientists demonstrated the utility of using the THAP/DAC MALDI matrix for peptide sequencing with DNA polymerase Beta tryptic peptide mixture, as well as tryptic peptides derived from Xiphophorus maculatus brain extract proteins previously separated by two- dimensional polyacrylamide gel electrophoresis (2D-PAGE).
Copyright © 2005 John Wiley & Sons, Ltd.
March 2005

LC/GC Europe face=verdana,arial published a paper by Bruker Daltonics Bremen and Surromed scientists entitled "Coupling LC with On-line ESI and Off-Line MALDI-MS/MS for Maximum Information Readout from Protein Samples" The LC-ESI-MALDI-MS/MS approach signficantly increased the number of unequivocally identified peptides from human serum samples by 30% compared to LC-ESI-MS/MS. Additional peptides are detected by MALDI-MS/MS since both techniques are complementary and MALDI-MS/MS does not suffer any temporal constraints. The novel WARP-LC software prevents the generation of redundant data and thus saves measurement time and sample amount remarkably.
March 2005

A new method to analyze matrix-assisted laser desorption/ionization time- of-flight peptile profiling mass spectra, using a Bruker Daltonics MALDI-TOF, was published in face=verdana,arial color=#0000a0 RCMface=verdana,arial by scientists at the Erasmus Medical Center in Rotterdam. This approach will aid the analysis of large numbers of mass spectra of patient samples in a reproducible way for the detection and validation of candidate biomarkers.
March 11, 2005

Wiley's InterScience published a research article by Bruker Daltonik scientists entitled "Glycoform characterization of intact erythropoietin by capillary electrophoresis-electrospray-time of flight-mass spectrometry."
March 9, 2005

Bruker BioSciences Dominates PITTCON With Most Proteomic Product Launches
ORLANDO, Fla. — When it came to unveiling new proteomics products at this year’s PITTCON meeting, held here this week, Bruker BioSciences dominated the field, launching three new mass spectrometers, three mass-spectrometry accessories, and a benchtop machine for high-throughput protein crystallization.
ProteoMonitor, March 4, 2005

Bruker BioSciences Reports Revenue of $85.8 Million, Operating Income of $3.6 Million and Net Income of $0.8 Million for the Fourth Quarter 2004
March 2, 2005

Both Bruker Daltonics and Bruker AXS made major product announcements at the Pittcon 2005 conference.
February 28, 2005

G.I.T. Laboratory Journal published a paper by Bruker Daltonics'
Director of Bioinformatics, Dr. Herbert Thiele, entitled Bioinformatics Solutions in Proteomics. Dr. Thiele points out that the challenge is to automate and integrate operations and procedures wherever possible in order to manage and process more effectively the growing volumes of proteomics data. He then explains how to do just that with sophisticated bioinformatics tools.
Volume 9, 2005

"Principles of Fourier transform ion cyclotron resonance mass spectrometry and its application in structural biology". This paper about the Bruker Daltonics 9.4 Tesla FTMS installation at the University of Warwick is currently appearing in the UK Royal Society of Chemistry's Journal "Analyst", available online..
January 2005

Rapid Communications in Mass Spectrometry published a paper by scientists at the University of Leige and Bruker Daltonik, Bremen entitled "Fast gas-phase hydrogen/deuterium exchange observed for a DNA G-quadruplex." The gas- phase hydrogen/deuterium (H/D) exchange kinetics of DNA G-quadruplexes has been investigated using Fourier transform ion cyclotron resonance mass spectrometry (FTICRMS).
January 2005

NewDrugs magazine from Germany reported on the new ProteoGenix and Bruker Daltonics collaboration on protein biomarker discovery and screening.....Dr. Gary Kruppa, Vice President of Bruker Daltonics, stated: "We are very pleased that ProteoGenix, a high profile and successful protein biomarker company, has chosen us as their strategic partner. Such customers validate our approach to developing a complete solution to biomarker discovery and identification.
November 2004

SEQUENOM, Inc. today reported that clinicians at the Baylor College of Medicine have published the successful implementation of the MassARRAY(R) mass spectrometry system for high- throughput Cystic Fibrosis testing. The publication in the September/October 2004 issue of Genetics IN Medicine also reports the discovery of a new disease causing polymorphism. The extended CFTR assay panel developed for use on SEQUENOM's MassARRAY system covers 51 mutations.
November 11, 2004

Medical News Today in an article entitled "Discovery may improve design, effectiveness of anti-cancer drugs" reported on a proteomics discovery made by University of North Carolina biochemists and colleagues at Bruker Daltonics headquarters. It was just reported in the Proceedings of the National Academy of Sciences.
October 19, 2004

Genetic Engineering News reviewed the Bruker Daltonics' ASMS new product announcements from May.
June 15, 2004

BThe Journal of Applied Crystallography published a research paper from the University of Aarhus entitled "A flux- and background-optimized version of the (Bruker AXS) NanoSTAR small-angle X-ray scattering camera for solution scattering."
June 2004

Bio IT World published a paper by Dr. Herbert Thiele, Bruker Daltonics' worldwide director of bioinformatics, entitled: A LIMS Can Help Mine the Results of Proteomics Research-- Combinations of experimental techniques are providing massive amounts of data, and new laboratory systems are enabling scientists to better understand that information.
June 2004

Dutch television news, Channel 1: Bruker Daltonics APEX- Q photos were shown on Dutch television for about 40 seconds as part of a fundraising event for important proteomics instruments at the Erasmus Medical Center in the Netherlands. The program appeared on the air on Saturday May 15, 20.00 hrs on the channel 1 Dutch national news "Het NOS Journaal"; which is the Saturday night prime time television with normally more than 1 million viewers. Interested people can watch the archived show at http://www.nos.nl/journaal/uitzendingen/videoarchief/index.html, (from 15.30 min to 17.30 min), a 2 min. 20 second item about the deficiency of funding for important proteomics instruments, according to the Erasmus Medical Centre. Prof. Ab Osterhaus (prof. in virology (f.i. SARS research) said, "Because of proteomics, the chance of breakthoughs in the research of serious medical problems like cancer and infection diseases have never been better."
May 15, 2004

Genetic Engineering News reviewed the Pittcon new product announcements from March.
Genetic Engineering News also interviewed Bruker AXS CTO Dr. Roger Durst regarding high-throughput tools for X-ray crystallography, and Bruker AXS' just-released automated crystal screening product, Crystal Farm(TM).
April 15, 2004

Analytical Chemistry published a paper entitled "Serum Peptide Profiling by Magnetic Particle-Assisted, Automated Sample Processing and MALDI-TOF Mass Spectrometry by Josep Villanueva, John Philip, David Entenberg, Carlos A. Chaparro, Meena K. Tanwar, Eric C. Holland, and Paul Tempst from the Protein Center, Research Engineering, Department of Surgery, Department of Neurology, Molecular Biology Program, and Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY. Ref: Volume 76, Number 6, Pages 1560- 1570. (Reprints available.)
March 15, 2004

Genetic Engineering News, in their front page story "Reorienting Mass Spec for Large Molecules" interviewed Bruker Daltonics' Mark Flocco Extensively. Flocco explained that Bruker Daltonics' main objective in developing MS systems for clinical proteomics and biomarker discovery is to put MS in the hands of biologists who have not typically used it until now. The article also gave extensive coverage to the Sequenom/Bruker Daltonics MassARRAY mass spectrometry for high-performance DNA analysis, including genotyping, gene- expression analysis, allele-frequency analysis, SNP discovery/mutation detection, and long-range haplotyping.
February 15, 2004

The Wisconsin Technology Network covered the announcement where "Bruker AXS has launched a new series of X-ray diffraction (XRD) systems for materials research applications, named SuperSpeedSolutions. The products are based on Bruker’s MikroGap technology that enables X-ray diffraction to go beyond current limitations in terms of sensitivity and speed."
January 14, 2004

Rockefeller University's Journal of Cell Biology published a paper by scientists at the French Institute of Health and Medical Research in Grenoble: AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. A Bruker Daltonics mass spectrometer was used to obtain MALDI mass spectra of peptide mixtures. Protein identification was confirmed by tandem mass spectrometry experiments.
January 5, 2004

LabOnline (Australia) analyzed Bruker Daltonics' participation in a workshop involving De novo sequencing of tryptic peptides. De novo sequencing has evolved to become a very useful tool for the complete elucidation of protein primary structures - especially in case of an unknown proteome. In a recent contest, MALDI-TOF/TOF MS has shown its huge potential for this task. The sequences of two unknown peptides were to be determined by MS/MS analysis from a 10 pmol sample. Bruker Daltonics participated with its two major proteomics systems, the ultraflex MALDI-TOF/TOF MS and the esquire3000 plus ESI-Ion Trap MS.
2003

CHANCE, a magazine of the American Statistical Association, published an article by Bruker Daltonics' Director of Bioinformatics, Dr. Herbert Thiele: "Mass Spectrometry and Bioinformatics in Proteomics". Vol 16, No. 4
Fall 2003

NewDrugs magazine printed a scientific article "PDF" by Bruker Daltonics' Dr. Detlev Suckau et al: "Structural Characterization of Recombinant Proteins by MALDI-TOF/TOF MS including Top-Down Analysis"
November 2003

ModernDrugDiscovery magazine interviewed Bruker Daltonics CEO Frank H. Laukien, Ph.D., in an article "PDF" entitled "Analytical sciences have always been a part of my life".
October 2003

EDINBURGH, Scotland, U.K.--(BUSINESS WIRE)--Sept. 1, 2003-- Bruker Daltonics Inc., a subsidiary of Bruker BioSciences Corporation (NASDAQ: BRKR - News), today introduces the autoflex(TM) TOF/TOF system, a compact high-performance MALDI-TOF/TOF mass spectrometer. This first vertical TOF/TOF system, which offers many of the high-performance MS/MS characteristics of larger TOF/TOF systems, requires less lab space, and is priced attractively at $375,000. .
September 2003

Drug Discovery & Development magazine published a writeup of selected Nuclear Magnetic Resonance user sites, including a Bruker LC-MS-NMR installation at Pfizer in Connecticut.
August 2003

Genetic Engineering News reviewed the Bruker Daltonics APEX Q Q-q-FTMS May 1, 2003

The Scientist magazine interviewed North American Sales & Marketing Director Victor Fursey about Bruker Daltonics' recent announcement of the microTOF in its article "High-Res Benchtop ESI-TOF".

The Bruker Daltonics and Bruker AXS Merger Agreement Announcement received significant coverage in newspapers like the Boston Globe and Boston Herald, together with being the lead story in Mass High Tech.

The German magazine NewDrugs wrote about Bruker Daltonics' Mayo Clinic "Collaboration to develop highly sensitive protein analysis methods-Advancing highthroughput proteomics with FTMS."

Proteomics Select published a scientific paper coauthored by Martin Schuerenberg of Bruker Daltonik: "Sample preparation protocols for MALDI-MS of peptides and oligonucleotides using prestructured sample supports." The protocols have been optimized for high detection sensitivity, robust performance, ease of use, and include sample purification and concentration. Some protocols were optimized for manual preparation of individual samples. Others were developed for the use of automated pipetting stations and optimized for high throughput protein identification and DNA sequence analysis. http://www.proteomicsvj.com/
March 18, 2003

Bruker Daltonics' major new products announced at Pittcon in Orlando received extensive coverage in publications such as ProteoMonitor.

Genetic Engineering News wrote on its front page: Bruker Daltonics entered into a proteomics collaboration with the Mayo Clinic that will focus on development of novel and more efficient methods for protein analysis using Fourier transform mass spectrometry. In a separate article, GEN described a 384-well Autoflex system performing high-throughput MALDI-TOF mass spectrometric analysis in quality control of oligonucleotides produced at MWG Biotech.

In an in-depth mass spectrometry survey, Genetic Engineering News reviewed the Bruker Daltonics Proteineer, ultraflex MALDI- TOF/TOF (with CID option), and AnchorChip product lines. The article included commentary by Hanno Langen, head of the proteomics initiative at Roche, who explained why they use more than 10 ultraflex-TOF/TOFs.

ProteoMonitor interviewed Bruker Daltonics customer and collaborator Professor Helmut Meyer at the Medical Proteome Center in Bochum, Germany. Professor Meyer mentioned that they use a Bruker Daltonics ultraflex coupled with several HPLCs. In this two page interview, he said they are also a Bruker Daltonics APEX FTMS user. He pointed out that they have two joint development projects with Bruker Daltonics: first, spot picker and automated digestion workstations, and second, bioinformatics software.

ProteMonitor interviewed Bruker Daltonics customer Dr. Hanno Langen, head of the proteomics initiative at Roche, who uses 10 Bruker Daltonics MALDI-TOF/TOFs. In this two page interview, he mentioned that one of the main reasons they decided for Bruker Daltonics instruments is that the instruments allow for easy integration with standard robotic systems since they use a standard microtiter plate format for their sample plates.

Science magazine interviewed Bruker Daltonics' President & CEO, Dr. Frank H. Laukien, in connection with his just being named CEO of the Year in Drug Discovery Tools by Frost & Sullivan. Highlights of the interview included:

On the need for collaboration among pharmaceutical companies, biotechnology firms, academic institutions, and regulatory authorities in drug development: "It's very important. We are an example of it. We have a number of collaborations with some small biotechnology companies. We also collaborate with startup biotech firms and large pharmas. Good collaborations of this type help us, as a tools provider, to help our pharmaceutical clients."

On the arrival of personalized medicine: "The personalized medicine approach will become more and more prevalent, perhaps for more than 50 percent of the drugs prescribed in 10 to 20 years. It will help to increase the safety of drugs for patients who really need them, while avoiding patients who can't benefit or who might be harmed."

Bruker Daltonics Grand Opening: CEO Frank Laukien and CFO John Hulburt cut the ribbon marking the building's opening. Bruker Daltonics scientist Ze Zhang explained the company's BioTOF II mass spectrometer (used to study proteins) to local scientists.
Lowell Sun photographs,

American, Japanese, and Swiss scientists won the Nobel Prize in chemistry yesterday for inventing techniques used to identify and analyze proteins, advances that revolutionized the hunt for new medicines. ... Because of their work, ''chemists can now rapidly and reliably identify what proteins a sample contains,'' the Royal Swedish Academy of Sciences said. ''They can also produce three-dimensional images of protein molecules in solution. Hence, scientists can both `see' the proteins and understand how they function in the cells.'' The techniques are also proving useful for diagnosing some cancers. John Fenn of the United States, Japan's Koichi Tanaka and Kurt Wuethrich of Switzerland all received the Nobel Prize in Chemistry for developing methods of identifying and analysing large biological molecules, such as proteins, using mass spectrometry and NMR instrumentation. Fenn and Tanaka produced their breakthroughs in the latter half of the 1980s, transforming the mass spectrometry analysis techniques.
Associated Press,
October 10, 2002

GenomeWeb gave in-depth coverage to Bruker Daltonics CEO Frank Laukien's presentation at the UBS Warburg Global Life Sciences Conference in New York.

Peptide mapping of proteins in human body fluids using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. A review from a team at Uppsala University of the use of a Bruker Daltonics 9.4 Tesla ultra high resolution FTMS to study the proteomes from body fluids. http://www.spectroscopynow.com/

GenomeWeb reviewed yesterday's announcement that researchers at Bruker Daltonics strategic partner GeneProt and Novartis are working with cardiologists at Duke University Medical Center to characterize distinctive protein expression patterns in heart disease patients. The detailed announcement included extensive commentary by GeneProt Chief Scientific Officer Keith Rose, Ph.D.

"This is the first time that in-depth proteomic analysis has been tackled on the scale of many liters of plasma, which is greater than 1,000 times more than is usually used, " Rose said. "This allows identification of proteins in low concentrations that may be novel and important factors in causing disease."
September 4, 2002

Genome Technology writes about proteomics research at the Danish Cancer Society's Institute of Cancer Biology. The Institute's Scientific Director, Dr. Julio Celis, uses 2D gels to separate proteins associated with disease prior to their identification by Bruker Daltonics MALDI-TOFs. Since 1980 he has built comprehensive, publicly-available databases of these proteins.

Dr. Celis also leads the planning for the first Human Proteome Organisation Congress coming up in November in Versailles, where Bruker Daltonics will both exhibit and make various scientific presentations.

Analytical Chemistry published a detailed review of the ion trap products available in the marketplace, including the Bruker Daltonics Esquire 2000 and 3000plus ion traps.

"Ion Traps Come of Age. Versatility and productivity make these instruments a popular choice for applications ranging from forensics to proteomics."
September 1, 2002

Genomic/Proteomic Technology discussed recent Bruker Daltonics product announcements related to Proteineer, TOF, TOF/TOF, FTMS, BioTOF-Q.
August, 2002

Nature Biotechnology is covering the Bruker Daltonics announcement of MetaboliteTools, a brand new software application for automated and interactive identification of drug metabolites using LC/MS.

Genetic Engineering News covered the Bruker Daltonics announcement of MetaboliteTools(TM), including MetabolitePredict(TM) and MetaboliteDetect(TM)

Nature Biotechnology covered the Bruker Daltonics announcement of GenoLink. "SNP accessory GenoLink, from Bruker Daltonics, is an automated accessory for MALDI-TOF mass spectrometry based SNP genotyping. It complements the Bruker Daltonics Proteineer suite and the company's MALDI-TOF systems for proteomics to......"

Genetic Engineering News covered the Bruker Daltonics and Matritech announcement of a partnership to develop an automated mass spectrometry system that will allow clinical laboratories to perform Matritech's proteomics-based cancer tests, including blood tests for breast and prostate cancer. It is anticipated that the new system will utilize MALDI-TOF mass spectrometry, automated sample handling, reagent kits, and clinical bioinformatics.

Genome Technology magazine's seven-page article on mass spectrometry this month included commentary by Bruker Daltonics' Dr. John Wronka, VP and General Manager, on the design benefits of both the Bruker Daltonics ultraflex and the FTMS. Dr. Wronka disclosed how the Bruker Daltonics ultraflex MALDI- TOF/TOF obtains its unsurpassed speed: "It's not just the laser rep rate, it's how fast you can get an MS/MS spectrum," he said. "We can get an MS/MS spectrum with 10 to 100 laser shots at 20 hertz. Whereas with the other instrument on the market, while the laser runs at 200 hertz, you need 1,000 or more shots."

"Because of the (FTMS') mass accuracy and the resolution, you can take a mixture of 100 proteins, digest them all together, and identify all 100," said Wronka.

Bruker Daltonics customer GeneProt provided additional commentary.

The Boston Globe today named Bruker Daltonics as one of its top Globe 100 companies in Massachusetts based on the company's financial performance. Bruker Daltonics ranks number eight in the Globe's listing of Massachusett's biggest "biotechnology" companies in terms of revenue. The Globe accompanied the text with another color photograph of a Bruker Daltonics engineer demonstrating the company's Chemical and Biological Mass Spectrometer. Bruker Daltonics CEO Frank Laukien attended the breakfast award ceremonies on behalf of the company.

Frost and Sullivan interviewed Bruker Daltonics' President and CEO, Dr. Frank Laukien.

ProteoMonitor discussed drug discovery at the Bayer Research Center in West Haven, CT, which integrates proteomics in several stages of the process. The Bayer installation includes a Bruker Daltonics Fourier Transform Mass Spectrometer. In addition, Bruker instrumentation at Affinium Pharmaeuticals was mentioned in the ProteoMonitor article "Affinium Breaks Ice With $30M Pfizer Deal." For the Cystic Fibrosis Foundation, Affinium will also study the protein-protein interaction of the CTFR protein and other membrane proteins..., in combination with its Bruker Daltonics mass spectrometry platform.

The Biacore Journal describes "Ligand fishing with Biacore 3000: selective binding, recovery and identification by MALDI-MS" Conclusions: SPR/MS tandem can be used to solve a typical proteomics problem, providing functional as well as structural data, including a target sequence and post-translational modifications. The calmodulin experiments demonstrate that the two technologies can be interlinked even without modification of the existing software and hardware. In addition, it was shown to be possible to prepare the sample recovered by SPR detection for MS analysis without the use of reverse phase columns. To read the full article, please click HERE.

Genetic Engineering News interviewed John Wronka, Ph.D., VP and General Manager, about the company's new APEX IV (TM) Fourier Transfer Mass Spectrometer. Dr. Wronka said, "Our design goal was to create a smaller, easier-to-use, yet more powerful FTMS system. The APEX IV represents MS technology for small- molecule analysis in metabolomics, combinatorial library analysis, natural products elucidation, and other areas requiring ultrahigh mass resolution and mass accuracy." .......

ProteoMonitor covered the proteomics group at Merck in New Jersey where the Bruker Daltonics FTMS mass spectrometer is among a comprehensive suite of proteomics technologies used in studying and identifying proteins. Merck mentioned that the FTMS is compatible with both MALDI and electrospray sources for looking at differentially labeled intact proteins. Merck's proteomics group is responsible for directing the company’s attempts at quantifying protein expression analysis, identifying surrogate markers in tissue and fluids, studying protein- protein interactions, and quantifying pharmacologically active peptide hormones.

Emergency Response and Disaster Management, the annual publication of the International Association of Emergency Managers, included an article about Bruker Daltonics entitled "Tools to Detect the Nature of NBC Attacks" -- Planning for nuclear, biological or chemical (NBC) attacks has assumed a new importance in recent months. The first step in dealing with these hazards is to ensure that first responders have the right instrumentation to quickly and accurately detect them.....

Genetic Engineering News presented detailed reports on the new Bruker Daltonics products announced at Pittcon, starting off with the ultraflex MALDI-TOF. "Using the same form factor as the company's recently launched MALDI-TOF/TOF, the ultraflex allows for an upgrade to TOF/TOF." Also described were the APEX IV Fourier Transform mass spectrometer, the atmospheric-pressure MALDI sources for the esquire3000plus and BioTOF-Q Q-q-TOF mass spectrometers, the new GenoLink solution accessory for MALDI-TOF for SNP genotyping, the omniflex LT, Bruker Daltonics' ProteinScape proteomics data warehousing and analysis software, and biotools and HyStar software upgrades.

PharmaGenomics' cover story describes "Applications for SPR-MS in Proteomics, From Isolation to Identification" Pharmaceutical companies feel increasing pressure to deliver returns on huge research and development investments in terms of marketable drugs and new chemical entities. One new process--a combination of surface plasmon resonance (SPR) and mass spectrometry--enables selective binding, recovery and identification of specific proteins from complex biological mixtures, helping to reduce R&D time and cost while increasing the quality and quantity of output. To read the full article, please CLICK here.
March/April 2002

ProteoMonitor covered the various March 18 Bruker Daltonics product announcements: "At Pittcon last week in New Orleans, Bruker Daltonics announced the release of three new instrument systems and additional bioinformatics software for use in proteomics research......"
March 25, 2002

Bruker Daltonics' President and CEO, Dr. Frank Laukien, was interviewed for the March issue of BioIt World in an article entitled "New Tools for Proteomics".
March 2002

The Bruker Daltonics expanded alliance with Roche was discussed in the feature article "Improved Proteomics Technologies" in Genetic Engineering News. Included in the article was an interview with Bruker Daltonics' head of MALDI-TOF Applications, Dr. Detlev Suckau. Dr. Suckau described the new Bruker Daltonics ultraflex MALDI-TOF/TOF, and discussed how this Bruker Daltonics MALDI-TOF/TOF, which has been selected by Roche, is able to do high-throughput protein identification with both high sensitivity and minimal sample consumption.
March 15, 2002.

Roche and Bruker Daltonics announced an expanded alliance in the field of proteomics. The resulting collaboration will focus on the development of highly efficient methods for mass spectrometric protein analysis. This news was discussed on Yahoo! FinanceVision by reporter Bertha Coombs. This press release is also available in Spanish. Click HERE for the Spanish version
January 25, 2002

Bruker Daltonics Chairman, President and CEO Frank Laukien, Ph.D., joined Nasdaq host Bob Power, Senior Vice President, to preside over the NASDAQ Market Open ceremony at Times Square in New York. The Nasdaq Stock Market senior executive proudly welcomed Bruker Daltonics to the Market Open ceremony and commended the company on successfully developing and providing innovative life science tools using mass spectrometry. This NASDAQ market opening program was broadcast on the web at www.nasdaq.com, along with live TV broadcasts on the Bloomberg, CNN, CNN FN, CNBC, Tech TV and Yahoo FinanceVision networks. In addition, KABC-TV in Los Angeles and WFTV-TV in Orlando/Daytona Beach broadcast the NASDAQ market opening by Dr. Laukien. Shortly thereafter, Dr. Laukien was interviewed individually by Tech TV, Dow Jones, Yahoo Finance Vision, and Reuters TV. The day's activities were also covered by FOX25 News in Boston. Click here for photographs of the event.
November 16, 2001

Please click here for the recent YAHOO! FinanceVision anchor interviews with Dr. Laukien.

The Cabot Market Letter (978-745-5532) in its two page analysis today selected Bruker Daltonics as its Cabot Stock of the Month, with "The inside story of a common stock with uncommon profit potential". They named Bruker Daltonics "The King of Mass Spectrometry".
November 9, 2001

Business Week discussed the Bruker Daltonics mass spectrometers used for chemical and biological agent detection, mentioning that Bruker Daltonics uses mass spectrometry to identify biological agents in the air in as little as three minutes and that recently "the U.S. Army announced a $10 million order for Bruker's analyzers."
November 5, 2001, page 42

Coverage initiated by Lehman Brothers. Kenneth Goldman of Lehman Brothers issues a "Buy" rating of Bruker Daltonics. Lehman analyst Kenneth Goldman said "Medical researchers are just starting the complex task of understanding the role of human proteins following the successful mapping of the human genome." Click here to read more.
October 26, 2001

Bruker Daltonics headquarters and products were featured on Boston evening news programs this week on the CBS, ABC, and FOX TV stations, along with anchor and reporter interviews with Bruker Daltonics President and CEO Frank Laukien and VP John Wronka. To view the channel 5 ABC TV program, please go to www.thebostonchannel.com/middaycallin/1016647/detail.html
Bruker Daltonics was also the lead story in the October 17th Boston Globe Business section, along with various FTMS, Autoflex and CBMS photographs.
October 19, 2001

Bruker Daltonics appeared on ABC's "Business Now" television program, this time in San Francisco on KGO on Sunday at 11:30 AM.
October 14, 2001

The Bruker Daltonics September 18th CBMS announcement has received coverage by Reuters, The Boston Globe, Mass High Tech, The New York Times, The Lowell Sun, Boston Business Journal radio, Defense News, Genome Web, and the UK's Sunday Business, among others.
September 30, 2001

Bruker Daltonics Announces Large DoD Order for Ion Trap Mass Spectrometers for Chemical and Biological Defense
September 18, 2001

Leading Swiss business and finance daily newspaper L'Agefi ran a full page story on Bruker Daltonics, including commentary by BDAL Vice President and General Manager John Wronka, Ph.D. The newspaper's analysis emphasized the Laukiens' role over the decades in building the business, the company's role as a leading proteomics supplier, its strong FTMS order rates, and its overall rapid growth.
September 3, 2001

Genome Technology magazine editorial: Bruker Daltonics' VP and General Manager, John Wronka, Ph.D., was interviewed by Genome Technology magazine's Editor-in-Chief, Adrienne Burke, in their editorial page. They discussed Bruker Daltonics' announced greater than 25% growth in life-science bookings in Q2 over the previous year, Bruker Daltonics' MALDI- TOF genomics business and the company's quickly expanding proteomics business. Dr. Wronka pointed out that Bruker Daltonics' creation of informatics tools is helping drive proteomics technology and its growth.
August 2001

Bruker Daltonics and Thermo Electron Settle Ion Trap Patent Litigation
August 30, 2001

Bruker Daltonics next appeared on ABC's "Business Now" television program, this time in our nation's capital, on WJLA on Sunday at 11:00 AM.
August 19, 2001

Frankfurter Allgemeine Zeitung -- "Proteomics A Strong Growth Industry" -- Proteomics could grow from a $560 million market to a $3 billion market in the next few years. Strong Bruker Daltonics MALDI-TOF sales in proteomics are discussed. http://www.faz.de/
August 18, 2001

Bruker Daltonics appeared on ABC's "Business Now" television program in Boston, WCVB, Channel 5 on Sunday at 9:00 AM.
August 12, 2001

Bruker Daltonics Second Quarter 2001 Product Revenue Up 31%, Profitability On Track For 50% EPS Growth in 2001
August 7, 2001

Bruker Daltonics appeared on ABC's "Business Now" television program in New York, WABC on Sunday at 11:00 AM.
August 5, 2001

Genomics Investing article:
"Market for Mass Spectrometers Expanding Steadily"
Growth in the functional proteomics industry is driving demand for mass spectrometers, reports Genomics Investing. Analysts predict that, long term, companies in this sector, including Bruker Daltonics, stand to benefit from increased research and development spending by drug developers and academic and government sources. And the mass spectrometer, known as the cornerstone of proteomics technology, will be a key driver of that increased spending. Bruker Daltonics is the only company to provide both the key MALDI-TOF and ion trap mass spectrometers, the article points out.
July 2001 Issue

Institutional Investor magazine article: "High-protein finance"
In April, GeneProt opened a first-of-a-kind proteomics discovery center in Geneva. The center has 51 Bruker Daltonics mass spectrometers working around the clock. Compaq has joined Bruker Daltonics and drug giant Novartis as strategic investors in GeneProt.
June 2001 Issue

Red Herring's Top 25 IPOs of 2000
May 31, 2001

Integrative Proteomics Completes First Pass Interrogation of the Proteome of Staphylococcus, a Major Disease Bacterium
May 15, 2001

Frank H. Laukien, Ph.D., President and Chief Executive Officer of Bruker Daltonics, Inc., will be a guest on JAGfn's
"The Trading Day" this Wednesday, May 9 at about 3:10 p.m. Eastern Time. Jagfn can be accessed worldwide on the web
with streaming video at http://www.jagfn.tv/ or http://www.quote.com/

May 7, 2001

Coverage initiated on Bruker Daltonics by Dain Rauscher Wessels
May 2, 2001

RW Baird Starts Coverage at Strong Buy
March 5, 2001

Easing Into Molecular Analysis
February 2001 issue of R&D magazine

The Wall Street Transcript Publishes Life Sciences Report In UBS Warburg Global Life Sciences Conference Issue
October 3, 2000

Hoover's Online IPO Scorecard for Third Quarter 2000 Suggests End of Dot-Com Honeymoon
October 2, 2000

Isis Pharmaceuticals' Ibis Therapeutics Division Wins R&D 100 Award
September 25, 2000